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Abstract 
Date: September 2012 
Name of student:  Shey Umaru Charles Wiysonge 
Title: Building evidence for improving childhood immunisation coverage in Africa 
The Expanded Programme on Immunisation has the potential to substantially reduce 
child mortality and contribute to achieving the Millennium Development Goals. We 
assessed the programme’s performance in Africa, the reasons for poor performance, and 
effective interventions for improving its performance on the continent. We used a 
combination of methods including systematic reviews, bibliometric analyses, generalised 
linear models, and grading of the quality of evidence.   
We found that African countries have made extraordinary advances since childhood 
immunisation programmes began in 1974. However, there exist wide inter-country and 
intra-country differences, and the quality of immunisation data is poor. Besides, vaccines 
are administered well after the recommended ages in many countries; leaving children 
exposed to deadly vaccine-preventable diseases for long periods. In addition, Africa’s 
contribution to the global immunisation research output is minimal. There is no 
association between research productivity and immunisation coverage in Africa, which 
may signal lack of interactive communication between policymakers and researchers. 
Furthermore, individual and contextual factors (defined at community and country levels) 
are independently associated with low immunisation coverage; suggesting that 
immunisation system strengthening should address people and the communities and 
societies in which they live. Lastly, we found moderate-to-high quality evidence that 
interactive educational meetings, audit and feedback, supportive supervision; and use of 
community health workers, parent reminders, home visits, interactive communication, 
mass media, and material incentives have the potential to improve childhood 
immunisation coverage in Africa. We recommend that these proven interventions should 
be an integral part of national immunisation action plans in Africa; accompanied by 
rigorous monitoring and evaluation to inform decisions being made. There is also a need 
for high-quality studies on other potentially useful interventions such as best approaches 
for integration with other primary care services, public stewardship of the private sector, 
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CHAPTER 1: General introduction  
 
1.1. About this chapter 
In this chapter, we provide general information about childhood immunisation 
programmes and related international health goals. In addition, we provide a motivation 
for doing the study and explain the objectives. 
 
1.2. The Expanded Programme on Immunisation  
Immunisation is widely acknowledged as one of the most powerful public health 
interventions available to improve child survival; not only by directly combatting some of 
the key diseases and causes of child mortality, but also by providing a platform for 
broader health services.1-7 The concentrated global effort to use vaccination as a public 
health intervention began when the World Health Organization (WHO) launched the 
Expanded Programme on Immunisation (EPI) in 1974, following an immensely successful 
worldwide smallpox eradication programme.8 The EPI programme typically consists of 
regularly scheduled services that reach each new cohort of children less than one year of 
age with vaccines at health facilities, scheduled outreach sites, or (in special 
circumstances) from door to door. When the EPI was launched in 1974, WHO 
recommended a standard immunisation schedule covering six basic antigens i.e. Bacille 
Calmette-Guérin (BCG), polio, diphtheria-tetanus-pertussis (DTP), and measles. The 
proportion of children who receive the full series of three doses of the DTP vaccine 
(DTP3) by 12 months of age is traditionally used as a standard measure of the 
programme’s ability to reach the target population, and is generally accepted to reflect the 
overall performance of EPI programmes.8  
The traditional EPI vaccines are estimated to annually prevent 2.5 million child deaths 
(mainly from measles, pertussis, tetanus, and diphtheria) as well as severe morbidity 
from devastating diseases such as poliomyelitis and tuberculous meningitis for millions 
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more. Introducing a portfolio of newly available vaccines (i.e. pneumococcal conjugate, 
rotavirus, and meningococcal group A conjugate vaccines)4, 5, 11-15  and under-utilised 
vaccines (such as Hepatitis B, Haemophilus influenzae type b, and yellow fever 
vaccines)16-20 into routine immunisation programmes of low and middle-income countries 
between now and 2015 could save the lives of millions more children. This would lead the 
world closer to achieving the Millennium Development Goals.3, 21 Table 1 shows a typical 
EPI schedule in Africa. Vitamin A supplementation is associated with large reductions in 
mortality in children aged 6 months to five years in low and middle-income countries; and 
it is included in the EPI schedule in Africa for this reason, even though it is not a 
vaccine.22 
Table 1: A typical EPI schedule in Africa 
Vaccine Doses Age Minimum interval 
BCG 1 Birth or soon after Not applicable 
OPV 4 Birth, 6,10,14 weeks 4 weeks 
DTP 3 6,10,14 weeks 4 weeks 
HepB* 3/4 Birth, 6, 10, 14 weeks 4 weeks 
Hib 3 6,10,14 weeks 4 weeks 
PCV 3 6,10,14 weeks 4 weeks 
RV** 2/3 6,10,14 weeks 4 weeks 
Measles*** 1 9 months Not applicable 
Yellow fever 1 9 months Not applicable 
Vitamin A 2 9, 15 months 6 months 
BCG, Bacille Calmette-Guérin; OPV, oral polio vaccine; DTP, diphtheria-tetanus-pertussis vaccine; HepB, 
Hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; PCV, pneumococcal conjugate vaccine; 
RV, rotavirus vaccine.  
* Some countries in Africa have a policy of giving a birth dose of the hepatitis B vaccine. 
** The Strategic Advisory Group of Experts (SAGE) has removed the maximum age restriction for rotavirus 
vaccine, but continues to recommend that the first dose be given as soon as possible after 6 weeks of age.    
.*** Measles vaccine is now recommended as a two-dose schedule, with the second dose given during the 
second year of life. 
 
 
1.3. Millennium Development Goals 
In the year 2000 the global community made a historic commitment to eradicate extreme 
poverty and improve the health and welfare of the world’s poorest people within 15 
years.23  The commitment is embodied in the United Nations Millennium Declaration, 
which spells out eight time-bound goals, known as the Millennium Development Goals 
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1. To eradicate extreme poverty and hunger;  
2. To achieve universal primary education;  
3. To promote gender equality and empower women;  
4. To reduce child mortality;  
5. To improve maternal health;  
6. To combat HIV/AIDS, malaria, and other diseases;  
7. To ensure environmental sustainability; and  
8. To develop a global partnership for development.23  
The MDGs are increasingly recognised as the over-arching development framework and, 
as such, are increasingly guiding the policies of low and middle-income countries, 
international agencies, and research projects; and this thesis is no exception.  
 
1.4. Global Alliance for Vaccines and Immunisation 
When EPI was born in 1974, global mmunisation coverage hovered around 5%. Through 
the 1980s, the United Nations Children Fund (UNICEF) and WHO led a successful global 
campaign to achieve Universal Childhood Immunisation with the six traditional EPI 
vaccines; by immunising at least 80% of all children by 1990. Unfortunately, other donor 
priorities overtook EPI in the 1990s and the programme suffered. Low and middle-income 
countries struggled to maintain childhood immunisation, and pharmaceutical companies 
had no incentive to invest in supplying vaccines to low-income countries. The outcome 
was that more than 30 million children were born annually in countries with inadequate or 
no childhood immunisation programmes.24 As a result of this failure to reach all children 
with life-saving vaccines, three million lives were lost each year due to vaccine-
preventable diseases. In response to this unacceptable situation, national governments, 
international agencies, non-governmental organisations, and the private sector came 
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GAVI’s aim is to save children's lives and protect people's health by increasing access to 
childhood vaccines in low-income countries. National governments of the 72 poorest 
countries of the world are eligible to apply for GAVI support. The GAVI model is designed 
to aggregate resources to create results beyond the capability of any single agency or 
country. It is also designed to make a rapid positive impact, using independent financial 
and administrative structures to ensure efficient transfer of support from donors to 
targeted countries. GAVI provides time-limited funding (usually over five years) for the 
supply of vaccines and other forms of support to strengthen implementing country 
immunisation services and health systems.20, 25, 26 27 
 
1.5. Global Immunisation Vision and Strategy 
In 2005, WHO and UNICEF launched the Global Immunisation Vision and Strategy 
(GIVS).28, 29 The primary objective of GIVS was to reduce vaccine-preventable disease 
mortality and morbidity by two-thirds by 2015 compared to 2000, which would be a 
significant contribution towards achieving the fourth Millennium Development Goal. GIVS 
presents a unifying vision and strives for a world in 2015 where immunisation would be 
highly valued and more people would be protected against more diseases. This vision is 
reflected in the over-arching goals, which relate to immunisation coverage, immunisation 
safety, sustainability, and disease reduction.  
GIVS has four strategic areas, namely:  
1. Protecting more people in a changing world;  
2. Introducing new vaccines and technology;  
3. Integrating immunisation, other linked health interventions, and surveillance in the 
health systems context; and 
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One of the targets set forth by GIVS was that all countries will achieve immunisation 
coverage of at least 90% at national level and 80% in all districts (to be measured by 
DTP3 coverage) by 2010, and to sustain these achievements through 2015. 28, 29 
 
1.6. Reach Every District 
Immunisation coverage declined or stagnated in the WHO African region (which 
essentially refers to sub-Saharan Africa) in the 1990’s. As a result, sub-Saharan Africa 
accounted for one-third of the estimated 33.4 million children globally who were un-
immunised (defined as children who did not receive at least three doses of the DTP 
vaccine by 12 months of age) in 2002.24 To reach these un-immunised children, the WHO 
African Regional Office and its partners developed the Reach Every District (RED) 
strategy as an innovative approach to improve childhood immunisation coverage in the 
region. 30, 31 The RED approach focuses on the district as the operational level and builds 
capacity at the district, health facility, and community levels to address common 
obstacles to routine childhood immunisation.  
The strategy focuses on five components, namely:   
1. Planning and management of resources;  
2. Supportive supervision;  
3. Re-establishment of outreach services;  
4. Community links with service delivery; and  
5. Monitoring and use of data for action.  
Beginning in late 2002, countries across sub-Saharan Africa were introduced to the RED 
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1.7. Decade of Vaccines Collaboration 
The Decade of Vaccines Collaboration (DoV) is newly created initiative which envisions a 
world in which all individuals and communities enjoy lives free from vaccine-preventable 
diseases.32 Its mission is to extend the full benefits of immunisation to all people by 2020 
and beyond, regardless of where the people are born, who they are, or where they live. 
The DoV was initially discussed by the 64th World Health Assembly in May 2011 as part 
of the progress report on the implementation of GIVS. Four Working Groups and a 
Steering Committee were set up within the DoV to develop the Global Vaccine Action 
Plan (GVAP). The former consisted of representatives of governments, civil society, 
health professionals, global development agencies, universities and research institutions, 
and vaccine manufacturers. The initial drafts of GVAP went through a consultation 
process that began in May 2011 and included global and regional meetings, dozens of 
issue-specific gatherings, and online consultations of a wide range of immunisation 
stakeholders. The final GVAP was endorsed by the 65th World Health Assembly in May 
2012 in Geneva.32 
 
1.8. Rationale of the project 
Through the efforts of national EPI programmes, and the assistance of the global 
initiatives discussed above, global DTP3 coverage rose from 17% in 1980 to 85% in 
2010.24, 33  However, Africa lags behind the rest of the world. DTP3 coverage in the WHO 
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Figure 1: Evolution DTP3 coverage from 1980 to 2010 by WHO Region 
 
 
Source: WHO [References 24 and 33; data as of July 2011] 
We believe that an evidence-based practice (EBP) approach34, 35 would improve the 
effectiveness, efficiency and equity of immunisation policies in Africa, and lead African 
countries to achieve the GIVS targets and eventually MDG-4. EBP, also referred to as 
evidence-informed policymaking, is the conscientious, explicit and judicious use of the 
best available research evidence when making healthcare decisions. 34, 35 An EBP 
approach to improving EPI programmes in Africa and, consequently, reducing child 
mortality on the continent demands first an understanding of why EPI has failed to reach 
its maximum potential. And secondly, appropriate corrective interventions to address the 
observed EPI challenges should be identified and implemented.36-39 These were the 
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1.9. Objectives of the project 
The aim of the thesis was to evaluate EPI performance in Africa, the reasons for poor 
performance, and effective interventions for improving EPI performance on the continent. 
The project focuses on child immunisation coverage, because the determination of 
immunisation status is the critical element of EPI performance assessment.8, 40, 41 The 
study combines several methods including bibliometric analyses, generalised linear 
models, systematic reviews, and grading of the quality of evidence of effects. 
 
The specific objectives of the project were: 
1. To assess routine childhood immunisation services, accelerated control of priority 
vaccine-preventable diseases, and introduction of new and underutilised vaccines 
in Africa (Chapter 2). 
2. To evaluate Africa’s contribution to the global immunisation research output; and 
to determine whether immunisation research productivity is associated with 
immunisation coverage in Africa (Chapter 3).  
3. To develop and test a model of childhood immunisation coverage that includes 
individual, community, and country-level characteristics (Chapter 4). 
4. To synthesise the global evidence from systematic reviews and randomised 
controlled trials of interventions for increasing immunisation coverage; and to 
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CHAPTER 2: The Expanded Programme on Immunisation in 
Africa  
 
2.1. About this chapter 
In this chapter, we report a systematic review of EPI performance in Africa. 
 
2.2. Introduction 
The 2015 deadline for the achievement of the Millennium Developme t Goals (MDGs) is 
less than five years away. Africa is significantly behind the rest of the world in making 
good its commitment to reduce child mortality by two-thirds42. Africa has the highest 
under-five mortality rate of all the world’s continents, with nearly half of all global deaths 
in under five year olds occurring in sub-Saharan Africa.42, 43 Globally, the under-five 
mortality rate reduced by 26% from 91 deaths per 1000 live births in 1990 to 67 deaths 
per 1000 live births in 2007; while in sub-Saharan Africa the rate decreased by only 20%, 
from 181 to 145 over the same period. Vaccine-preventable diseases are a major 
contributor to high African child mortality rates, partly because of the limited introduction 
of new vaccines and low uptake of existing vaccines.44 In 2010, only 77% of African 
infants received the full series of three doses of the diphtheria-tetanus-pertussis vaccine 
(DTP3). Overall more than seven million children in Africa did not receive DTP3 by one 
year of age in 2010.24, 33 Furthermore, vaccine efficacy tends to be lower in low-income 
countries than in higher-income countries,5, 45 thus the need to attain and sustain high 
and equitable childhood immunisation coverage in sub-Saharan Africa; where most 
countries are low-income. We assessed the performance of EPI in Africa, with a focus on 
the determination of immunisation status. There is consensus within the EPI community 
that the critical element of EPI performance evaluation is routine immunisation coverage. 
8, 40, 41 The latter is the output of a system which involves a series of inter-related 
components; such as training, vaccine delivery, financing, vaccine logistics, and 
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immunisation system as well as progress in the accelerated control of priority vaccine-
preventable diseases on the African continent. 
 
2.3. Methods 
From July 2011 to July 2012, we searched websites of WHO and other international 
agencies (as shown in Table 2) for information on the performance of national EPI 
programmes in Africa. We supplemented this targeted grey literature search with 
searches of Africa-Wide and PubMed databases, for peer-reviewed data published 
between 1970 and 2010 on childhood immunisation programmes in Africa. The search 
strategy used for each database is shown in Table 2. 
 




3. http://www.emro.who.int/entity/vpi/  





9. http://www.msf.org/  
Search strategy for PubMed: 
"Immunization"[Mesh] OR "Vaccination"[Mesh] OR "Immunization, Secondary"[Mesh] OR 
"Immunization Programs"[Mesh] OR "Immunization Schedule"[Mesh] OR "Immunization, 
Passive"[Mesh] OR "Mass Vaccination"[Mesh] AND ((ALGERIA) OR (ANGOLA) OR (BENIN) OR 
(BOTSWANA) OR (BURKINA FASO) OR (BURUNDI) OR (CAMEROON) OR (CANARY ISLANDS OR 
"CANARY ISLANDS") OR ((CAPE VERDE) OR "CAPE VERDE") OR (CENTRAL AFRICAN 
REPUBLIC) OR (CHAD) OR (COMOROS) OR (CONGO) OR (DEMOCRATIC REPUBLIC CONGO) 
OR (DJIBOUTI) OR (EGYPT) OR ((EQUATORIAL GUINEA) OR "EQUATORIAL GUINEA") OR 
(ERITREA) OR (ETHIOPIA) OR (GABON) OR (GAMBIA) OR (GHANA) OR (GUINEA) OR ((GUINEA 
BISSAU) OR "GUINEA BISSAU") OR (IVORY COAST) OR ((COTE D'IVOIRE) OR "COTE D'IVOIRE") 
OR (KENYA) OR (LESOTHO) OR (LIBERIA) OR (LIBYA) OR (LIBIA) OR (JAMAHIRIYA) OR 
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OR (MOROCCO) OR (MOZAMBIQUE) OR (MOCAMBIQUE) OR (NAMIBIA) OR (NIGER) OR 
(NIGERIA) OR (REUNION) OR (RWANDA) OR ((SAO TOME) OR "SAO TOME") OR (SENEGAL) OR 
(SEYCHELLES) OR ((SIERRA LEONE) OR "SIERRA LEONE") OR (SOMALIA) OR ((SOUTH 
AFRICA) OR "SOUTH AFRICA") OR ((ST HELENA) OR "ST HELENA") OR (SUDAN) OR 
(SWAZILAND) OR (TANZANIA) OR (TANGANYIKA) OR (TOGO) OR (TUNISIA) OR (UGANDA) OR 
((WESTERN SAHARA) OR "WESTERN SAHARA") OR (ZAIRE) OR (ZAMBIA) OR (ZIMBABWE) OR 
(AFRICA[MH]) OR (SOUTH* AND AFRICA*) OR (WEST* AND AFRICA*) OR (EAST* AND AFRICA*) 
OR (NORTH* AND AFRICA*) OR (CENTRAL* AND AFRICA*) OR (SUB SAHARAN AFRICA*) OR 
(SUBSAHARAN AFRICA*) OR (AFRICA*) NOT (((GUINEA PIG*) OR "GUINEA PIG*") OR 
((ASPERGILLUS NIGER) OR "ASPERGILLUS NIGER"))) AND ("Infant, Newborn"[Mesh] OR 
"Infant"[Mesh] OR "Child, Preschool" [Mesh]) 
 
Limits: Humans, Publication Date from 1970/01/01 to 2010/12/31  
Search strategy for Africa Wide: 
KW ( "Immunization" OR "Vaccination" OR "Immunization, Secondary" OR "Immunization Programs" 
OR "Immunization Schedule" OR "Immunization, Passive" OR "Mass Vaccination" OR "Vaccine" ) 
AND KW ( infant OR newborn OR child* )  
Limiters - Scholarly (Peer Reviewed) Journals; Year Published: 1970-2010 
 
We screened the search outputs in duplicate and selected publications which focused on 
immunisation or the “traditional” vaccine-preventable diseases (measles, diphtheria, 
tetanus, pertussis, and poliomyelitis), were conducted in an African country, and had 
human beings as the subject. From the final pool of studies we selected (by consensus) 
key websites and peer-reviewed publications with relevant data on immunisation 
coverage, components of the routine immunisation system, accelerated control of priority 
vaccine-preventable diseases, and introduction of new and under-utilised vaccines in 
Africa. For immunisation cov rage, we conducted quantitative analyses of district and 
national data as described below. For other aspects of EPI performance, we conducted a 
narrative synthesis of the information contained in the selected publications. We collected 
and reported data from all the 53 countries on the African continent, unless in instances 
where relevant data were only available for the WHO African Region.  
We conducted data management and statistical analyses of routine immunisation 
coverage data using Microsoft Access, STATA 10, and ArcGIS software. We compared 
national coverage for DTP3, first dose of measles-containing vaccine (MCV1), and BCG 
from the end of each decade since the onset of EPI in 1974 to 2010. We also used the 
reported data for the first and third dose of DTP (i.e. DTP1 and DTP3 respectively) to 
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measures the proportion of children who received the first dose of a vaccine and failed to 
come back for the remaining doses. A drop-out rate of less than 10% was considered 
acceptable. In addition, we used the reported tetanus toxoid coverage data for pregnant 
women to calculate the proportion of newborns protected from tetanus at birth (PAB). The 
latter refers to at least 80% coverage with two or more doses of tetanus toxoid (i.e. TT2+) 
in pregnant women. Furthermore, we used WHO and UNICEF estimates of national 
immunisation coverage for BCG, DTP1, DTP3, MCV1, and PAB.46   
 
2.4. Results of the peer-reviewed literature search 
The search and selection process of peer-reviewed articles on EPI in Africa is shown in 
Figure 2. We identified 1897 records in PubMed and 3539 records in Africa Wide, 
published between 1 January 1970 and 31 December 2010. After screening the titles and 
abstracts, we excluded 1200 articles from PubMed and 2877 articles from Africa Wide; 
which were clearly not on an operational aspect of childhood immunisation programmes 
in Africa. Of the remaining 1359 articles, the full text publications of 113 articles were not 
available and we excluded them from further review. We then reviewed the full text 
publications of the remaining 1246 articles, from which we excluded 365 duplicate 
publications and 227 reports of phase 1-3 randomised controlled trials and clinical 
management of vaccine-preventable diseases; because these were not directly relevant 
to EPI operations.  
The remaining 654 articles contained information on various aspects of the planning, 
implementation, monitoring, and evaluation of immunisation activities in 47 African 
countries. The 654 articles were categorised as follows: 334(51%) were on programme 
management issues, 114(17%) were vaccine effectiveness studies, 101(15%) were 
epidemiological or burden of disease studies, 82(13%) were on vaccine policy making, 
and 23 (4%) were on vaccine financing. These studies were published in 156 different 
scientific journals with citation impact factors ranging from 0 to 53.29; where 62% had an 
impact factor from 2 to 10, and 11% had an impact factor greater than 10.  
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Figure 2: Search and selection of EPI articles from peer-reviewed literature 
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2.5. Routine childhood immunisation services 
 
2.5.1. Routine childhood immunisation coverage 
According to WHO and UNICEF coverage estimates (available since 1980),46 the number 
of African countries with national DTP3 coverage of at least 90% increased from 0(0%) in 
1980, through 7(13%) in 1990 and 9(17%) in 2000, to 22(42%) in 2010.24 The 
improvements in national DTP3 coverage between 1980 and 1990 as well as between 
2000 and 2010 were significant (all p<0.001). However, there were no significant 
differences in national DTP3 coverage between 1990 and 2000 (probably due to 
decreased external funding when the Universal Childhood Immunisation campaign 
ended). Figure 3 shows the evolution in national DTP3 coverage in Africa since 1980. 
Similar to national DTP3 coverage, we also observed a steady improvement in the 
proportion of countries having an acceptable DTP drop-out rate (i.e. less than 10%)  from 
1980 till 1990, stagnation between 1990 and 2000, and a significant (p=0.0013) increase 
between 2000 and 2010.  
District immunisation data from WHO/UNICEF Joint Reporting Forms (please see section 
2.5.2. below) were available for 2005 and 2010.24 In 2005, sixteen (30%) African 
countries reported 80% DTP3 coverage in at least 80% of their districts. District DTP3 
coverage data were not available for two countries (Algeria and Djibouti) in 2005. In 2010, 
no improvement was observed as only 16 (30%) countries reported 80% DTP3 coverage 
in at least 80% of their districts. District DTP3 coverage data were not available for three 
countries (Cape Verde, Libya, and Rwanda) in 2010.   
In addition, the quality of immunisation data in many African countries is questionable.47-
49 External evaluations have encountered difficulties in verifying vaccine doses 
administered in health facilities; usually as the result of discrepancies in information 
between health facilities and their corresponding districts or because completed recording 
forms were not available at the health facilities visited. Weaknesses in the monitoring of 
immunisation data are common in most countries. These include inconsistent use of 
coverage monitoring charts; inadequate monitoring of vaccine stocks, injection supplies, 
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and timeliness of reporting of data. 47-49 Furthermore, in many African countries, vaccine 
doses are administered well after the recommended ages; leaving children exposed to 
deadly vaccine-preventable diseases for long periods. These delays vary widely, between 
and within countries.50 
 
Figure 3: Evolution of national DTP3 coverage in Africa from 1980 to 2010 
 
NB: The maps show North African countries (which belong to the WHO Eastern Mediterranean Region) 
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2.5.2. Collection of routine childhood immunisation data 
In this section, we summarise our understanding of how childhood immunisation data are 
collected and disseminated; from the remotest rural vaccination centre in Africa to the 
headquarters of WHO in Geneva and UNICEF in New York. Healthcare workers collect 
administrative data on the number of vaccinations given, in tally sheets or immunisation 
registers at the immunisation delivery point, and report to local authorities. These data 
are aggregated and reported (at regular intervals e.g. monthly or quarterly) to higher 
administrative levels, up to the central level.8, 19 Each year, WHO and UNICEF jointly 
collect the administrative immunisation data from countries through a standard 
questionnaire known as the WHO/UNICEF Joint Reporting Form. Data collected in the 
Joint Reporting Form (JRF) include estimates of national immunisation coverage, 
reported cases of vaccine-preventable diseases, immunisation schedules, and 
immunisation system performance indicators. Countries send the completed JRF to WHO 
and UNICEF by April of the following year, and these are available on the web in July.24, 
33  
WHO and UNICEF use the administrative coverage data reported by countries, 
supplemented by coverage data from surveys reported in peer-reviewed and grey 
literature, to produce WHO/UNICEF estimates of national immunisation coverage.46, 51 
WHO and UNICEF also consult local experts, especially national EPI managers and 
WHO/UNICEF regional and national staff, for additional information on the performance 
of specific immunisation systems. The information is used to derive immunisation 
coverage estimates through a country-by-country review of available data informed and 
constrained by a set of heuristics; without applying any statistical or mathematical 
models. Draft WHO/UNICEF national coverage estimates are sent to national authorities 
for review and comment, and then modified accordingly. The WHO and UNICEF indicate 
that while the final immunisation coverage estimates may or may not differ from reported 
administrative data, the estimates constitute an independent technical assessment of the 
performance of national immunisation systems by WHO and UNICEF. The two United 
Nations agencies have been deriving these annually updated country-specific national 

















Training needs assessments in 14 countries in sub-Saharan Africa in the late 90s 
referred to the needs for management training, bottlenecks between pre- and in-service 
training, poor coverage of EPI topics in training curricula, and lack of training of teachers 
in EPI.52, 53 This led the WHO African Regional Office to institute the Mid-Level 
Management (MLM) training courses in the region; to provide EPI managers with new 
and advanced skills in planning, management, monitoring and evaluation. An external 
evaluation was conducted in 2005 of the MLM training held between 2000 and 2004 in 
the African Region, to assess its effectiveness and impact, and its contribution to EPI 
management. The evaluation consisted of  a desk review of the MLM course reports, 
MLM modules and reference documents; interviews with MLM course participants, 
facilitators, supervisors, ministry of health officials and country-based partners; and focus 
group discussions.  
The evaluation revealed that during 2000-2004, eleven MLM courses were held and 642 
participants trained. The latter included 416 EPI managers, 110 lecturers from institutions 
that train health workers, 114 WHO/UNICEF immunisation focal persons, and others. The 
110 academic staff who received MLM training went back to their institutions and 
introduced change in EPI teaching, based on new developments and strategies in EPI 
(such as GIVS and RED). Through perception of users and country-based EPI 
stakeholders, satisfaction index results and observations in the field during the external 
evaluation, it was evident to the evaluators that the MLM training had increased the 
performance of the trained staff and therefore contributed to the improvement of EPI 
coverage in the African Region. Using DTP3 as an indicator, immunisation coverage in 
the African Region increased from 53% in 2001 to 69% in 2004.  
Other collateral benefits of the MLM course included development of capacity building 
plans by country teams during the course of training; development by the host country of 
a solid pool of facilitators for national EPI and other MLM courses; extra-regional 
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other WHO regions. All MLM modules were scored very highly by course participants and 
facilitators. However, the evaluation found that the MLM courses were predominantly 
vertical, and that follow-up of trained managers or facilitators was not consistent. The 
evaluation team also observed that there was a lack of a reliable database on EPI 
training activities to keep the institutional memory on training and support capacity 
building analysis by EPI programme management. Furthermore, there was insufficient 
involvement and use of the private sector in MLM training. 40, 41 
 
2.5.4. Vaccine delivery 
We describe here the implementation of the RED approach in the WHO African Region, 
as a proxy for the status of immunisation service delivery in Africa. Implementation of the 
RED approach began in early 2003 through the provision of technical and financial 
support to several countries.30, 31 In June 2005, an external evaluation of RED was 
conducted in a convenience sample of five countries (Democratic Republic of Congo, 
Ethiopia, Kenya, Madagascar, and Zimbabwe).30 At that time, 26 countries were 
implementing the RED approach in the WHO African Region. The evaluation revealed 
that the implementation of RED in each country started with training and micro-planning. 
All five RED components were implemented to some degree in the five countries. Some 
of the common implementation factors included development of plans, expanding 
outreach services (defined as services provided in sites outside fixed immunisation sites), 
planning of supervisory visits, and efforts to link with communities and utilise community 
health workers. Monitoring tools such as wall charts and maps were observed and 
reportedly used.  
In 2007, a further and more extensive RED evaluation was conducted throughout the 
year.31, 53 The nine countries visited were Benin, Cameroon, Democratic Republic of 
Congo, Ethiopia, Ghana, Madagascar, Sierra Leone, Togo, and Uganda. These countries 
differed in how quickly they expanded RED, with a few of them rolling-out nationally and 
others starting with a few priority districts and phasing‐in new districts gradually. By 2006, 
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introduced RED as a package, the emphasis in each country was different. In 80% of the 
68 districts visited, outreach was the component mentioned most often by the staff in 
describing what RED meant in their districts. The most notable changes since the 
introduction of the RED approach, as noted by district staff, were additional outreach sites 
and community meetings.  
Regarding planning and resource management, annual EPI action plans were available 
in all countries at the central level, in most districts and in half of the 133 health facilities 
visited. Only half of district micro-plans indicated hard‐to‐reach populations and strategies 
for reaching them. Vaccine stock-outs occurred within the last year at the district and 
health facility levels in eight of the nine countries visited. Training and managerial 
capacity gaps were found in a majority of districts. Few district or health facility staff had 
received recent immunisation training and there was a rapid turnover of staff in several 
countries, resulting in an increasing proportion of untrained EPI staff. Regarding 
supportive supervision, two-thirds of districts included supervision in their annual work 
plans. However, only a third of the districts reported that they had received supervisory 
visits from the central level in the three months preceding the evaluation. Supervisory 
visits from districts to health facilities occurred more frequently; two-thirds of health 
facilities reported receiving supervisory visits in the three months preceding the 
evaluation. Supervisory checklists were commonly used (four-fifths of health facilities) 
and supervision of EPI was integrated with that of other health services in six of the nine 
countries. While four-fifths of health facilities reported receiving immediate verbal 
feedback, written supervisory feedback was documented in only one-third of the health 
facilities. District review meetings occurred in almost all districts. Regarding outreach 
activities, district and health facility staff identified outreach sessions as a positive 
contributor to immunisation service delivery. Most countries reported an increase in the 
number of outreach sessions planned and held since the introduction of RED, and 
outreach was commonly linked to other maternal and child health interventions. 
Regarding community links with service delivery, the RED evaluation showed that 
community health workers were active in all countries; assisting with defaulter tracking, 
outreach, and community education. Two‐thirds of health facilities reported holding 
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community health workers had been trained to assist with EPI activities. Half of the health 
facilities reported that the community health workers were provided with material 
incentives such as training or re‐imbursement of transport costs. Regarding monitoring 
for action, immunisation monitoring charts were displayed in the majority of districts and 
health facilities, and most were correct and up‐to‐date. Health workers in two-thirds of 
facilities with monitoring charts were able to explain their facility’s performance. Ninety 
five percent of districts reported that they conducted review meetings with their health 
facilities during the 12 months preceding the evaluation, at which they discussed 
immunisation data. The problems identified by this RED evaluation have been reported 
by EPI managers in other African countries.54 
 
2.5.5. Financing of childhood immunisation services 
By 2010, 96% of African countries had developed comprehensive multiyear immunisation 
plans with appropriate costing.24, 53 Eighty-five percent of sub-Saharan African countries 
had a specific line in their national budget for procurement of vaccines used in routine 
EPI.23, 41 The proportion of government funding of the overall expenditure on EPI 
vaccines in sub-Saharan Africa rose from 48% in 2000 to 53% in 2006. However, the 
proportion of government funding of overall routine EPI expenditure remained virtually the 
same at 43-45% between 2000 and 2006. 
In 2005, according to information reported in the Joint Reporting Form,24 49% (26/53) of 
African countries reported that at least half of the costs of their routine vaccines were 
funded by their respective governments.24 However in 2008, only about 15% of the 34 
USD per infant needed for routine EPI was met from government funds.23 This shortfall is 
due to rising EPI costs, which pose significant challenges to governments. The cost of 
fully immunising a child today actually exceeds the total per capita government spending 
on all health care in a majority of African countries. External donor support has helped 
many African countries to keep pace with rising EPI costs.26 Adding newly available and 
under-utilised vaccines (as discussed below) to national routine immunisation 
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many African countries.26  The 2007 evaluation of the RED Approach in the WHO African 
Region indicated that countries have used WHO and UNICEF grants, support from 
Non‐Governmental Organisations (NGOs), GAVI funds, and national and district health 
budgets to finance EPI activities.30, 31  However, the funding (from the various sources) 
was still not sufficient to meet all EPI needs. 
 
2.5.6. Other priority routine immunisation issues in Africa 
With regards to vaccine safety, in 2005, 40(77%) African countries reported having 
adequate national supplies of auto-disable syringes (the recommended vaccine delivery 
method).24, 55 This figure had not changed by 2010. Again in 2005, 42(79%) African 
countries reported having a medical waste management system in place; and 87% 
(46/53) reported national distribution of safety boxes. In 2010, we observed an increase 
in the proportion of countries that reported national distribution of safety boxes to 89%, 
but there was no change for medical waste management.24  
Integration of health services brings together common functions within and between 
organisations to solve common problems, developing a commitment to a shared vision 
and goals, and using common technologies and resources to achieve these goals.3,6, 55 
The RED evaluation indicated that the provision of immunisation with other maternal and 
child health services were common in health facilities and outreach sessions. Other 
authors have also provided evidence of limited integration of other interventions to EPI 
services in African countries.3, 7 Co-administered interventions included Vitamin A 
supplementation, family planning, antenatal care, distribution of insecticide-treated 
bednets, deworming of children, growth monitoring, and curative care. 
In many countries there is an inadequate infrastructure, an insufficient number of 
healthcare workers to administer vaccines, and a lack of appropriate EPI training.53, 54 
The inadequate infrastructure includes lack of cold chain equipment, transportation 
logistics and inadequate road system; which are present in various degrees in most 
countries.  Some countries also report insufficient numbers of health facilities, resulting in 
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2.6. Accelerated control of vaccine-preventable diseases 
Based on the success of the smallpox eradication programme and increasing global 
routine immunisation coverage, specific disease control objectives were added to the EPI 
by WHO global and regional governing bodies. Accelerated vaccination strategies for 
attaining these objectives included high routine immunisation coverage, mass vaccination 
campaigns (also referred to as supplementary immunisation activities), and active case-
based surveillance with laboratory confirmation.7, 8, 10, 45, 56, 57 
2.6.1. Eradication of poliomyelitis 
Since the Global Poliomyelitis Eradication Initiative was launched in 1988, there has been 
significant progress in the interruption of wild poliovirus circulation; with certification of 
eradication in WHO Regions of the Americas in 1994, Western Pacific in 2000, and 
Europe in 2002.58  However in African countries, the eradication of poliomyelitis is not yet 
as successful as in the Americas, Western Pacific, or Europe. 
Poliomyelitis caused by the wild poliovirus was endemic in 12 African countries in 2000. 
Between 2000 and 2002, the number of endemic countries decreased to two; and 
reported new cases of polio declined by 89% from 1863 to 208. 48 Following cessation of 
polio vaccination in northern Nigeria in September 2003 amidst speculation that the oral 
polio vaccine was contaminated with contraceptive and infectious particles, wild polio 
virus spread from Nigeria to eight other African countries by the end of 2003.10, 59 In total, 
from 2003 to 2011 wild polio virus was imported from Nigeria into 29 previously polio-free 
African countries. However, intensified efforts at country and continental levels in Africa 
since 2010 have resulted in the number of reported wild polio virus cases on the 
continent dropping by 47% from 657 in 2010 to 350 in 2011.53, 58, 60 Despite this 
significant improvement, in 2011, polio was still endemic in one country (Nigeria), had re-
established transmission in three countries (Angola, Chad, and Democratic Republic of 
Congo), and was imported to ten others (Central African Republic, Congo, Cote d’Ivoire, 
Gabon, Guinea, Kenya, Liberia, Mali, Niger, and Uganda).58 A previously polio-free 
country is said to have re-established transmission if active wild poliovirus transmission 
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significant progress towards polio eradication in Africa. From January to July 2012, two 
re-established transmission countries (Angola and Democratic Republic of Congo)  and 
four importation countries (Niger, Mali, Liberia, and Cote d’Ivoire) did not report any new 
cases of paralysis due to the wild poliovirus.53 
Case-based surveillance in the context of polio eradication consists of surveillance of 
acute flaccid paralysis (AFP), which has been established in all African countries. The 
two main surveillance indicators (non-polio AFP rate of at least 2 per 100,000 inhabitants 
below 15 years of age, and stool specimen collection rate of at least 80% within 14 days 
from date of onset of paralysis) are consistently met at national level in the majority of 
countries. However, sub-optimal surveillance performance is commonplace at district 
level, and inadequate capacity to conduct high-quality outbreak investigations still pose 
challenges to achieving polio eradication in Africa. 
 
2.6.2. Accelerated control and elimination of measles 
Routine vaccination with the first dose of a measles-containing vaccine (MCV1) at nine 
months of age was implemented in most African countries by 1980. However because of 
sub-optimal MCV1 coverage, measles outbreaks remained widespread. Nearly one 
million children died from measles worldwide annually, half of them in Africa.  This led the 
World Health Assembly (WHA) in 1989 and the World Summit for Children in 1990 to set 
the goal for measles mortality reduction of 95%, compared with pre-vaccine levels.53, 56, 61, 
62 The key strategies of the measles mortality reduction goal were: vaccination through 
routine health services (MCV1); nationwide catch-up supplementary immunisation 
activities (SIAs) among children aged 9 months to 15 years of age; follow-up SIAs every 
3-4 years among children aged 9-59 months; improved management of measles cases; 
and case-based measles surveillance with laboratory confirmation to monitor and assess 
the impact of the vaccination activities.  
From 1996 to 2000, seven southern African countries (Namibia, Botswana, South Africa, 
Zimbabwe, Malawi, Swaziland, and Lesotho) implemented the recommended measles 
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the catch-up measles SIAs in these countries, with overall reported vaccination coverage 
of 91%. Thereafter, with the financial and technical support of the Measles Initiative, all 
African countries (except Algeria, Mauritius, Seychelles and Morocco) conducted at least 
one catch-up nationwide SIA between 2000 and 2010.7, 56, 61-67 Most of the SIAs were 
high-quality and achieved administrative coverage of 95% or more. Apart from SIAs, 
countries are recommended to introduce a routine second dose of a measles-containing 
vaccine (MCV2). Eleven countries in the WHO African Region had introduced MCV2 by 
2011, two more introduced in 2012, and at least 30 countries are expected to have 
introduced MCV2 by 2015.53 The implementation of the measles mortality reduction 
strategies resulted in a dramatic reduction in measles deaths on the continent. As shown 
in Figure 4, measles deaths in sub-Saharan Africa reduced by 92% between 2000 and 
2008 (from 371,000 to 28,000 deaths); mainly as a result of the high-quality SIAs.61, 66  
 
















Following the significant reduction in measles deaths, the WHO African Regional Measles 
Technical Advisory Group proposed the adoption of a measles pre-elimination goal to be 
met by 2012. The African Regional Task Force for Immunization endorsed the proposal in 
December 2008. In 2009 the 59th session of the WHO Regional Committee for Africa 
adopted a regional goal of measles elimination by 2020, with an interim goal of pre-
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The measles pre-elimination targets were stated as:  
1. More than 98% reduction in measles mortality between 2000 and 2012; 
2. Less than 5 cases per million inhabitants per year in all countries;  
3. More than 90% of countries achieving MCV1 coverage of at least 90% at 
national level and at least 80% in all districts;  
4. At least 95% SIA coverage in all districts; and  
5. All countries having high-quality measles case-based surveillance.53 
The progress in measles control in Africa, however, has been compromised by sub-
optimal routine measles immunisation coverage at district level in many countries. In 
2005, only 11(21%) African countries reported at least 80% routine first-dose measles-
containing vaccine (MCV1) coverage in at least 80% of their districts. This proportion 
increased only slightly to 32% (17/53) in 2010.24  With regards to national routine MCV1 
coverage, 23(44%) countries reported less than 80% MCV1 coverage in 2010; with two 
countries (Chad and Somalia) having less than 50% MCV1 coverage at national level.24 
Due to the low MCV1 coverage and delayed or sub-optimal follow-up SIAs, 27 countries 
in Africa experienced widespread measles outbreaks between 2009 and 2011.61, 65, 68-70 
 
2.6.3. Control of yellow fever 
Thirty three African countries are considered to be at risk for yellow fever.53 By 2000, 27% 
(9/33) of these countries had introduced yellow fever vaccination into their EPI schedules. 
And in 2010, 81% (27/33) reported yellow fever vaccination in their EPI schedules.19, 24, 53 
However, there have been more than 20 outbreaks of yellow fever since 2000.  Most of 
these occurred in districts with rural settlements but a few urban outbreaks were also 
recorded.19, 53 Since 2001, a global stockpile of yellow fever vaccines has been set up for 
access to vaccines for emergency response to yellow fever outbreaks. With GAVI 
support, this stockpile was increased to six million doses of yellow fever vaccine per year 













Charles Shey Wiysonge: PhD Thesis 
 
vaccine were administered during preventive yellow fever SIAs conducted between 2006 
and 2009 in nine selected GAVI-eligible countries in Africa.53   
 
2.6.4. Elimination of neonatal tetanus 
Neonatal tetanus remains a major public health problem in Africa.24, 71 It was estimated 
that 18(67%) out of the 27 countries that accounted for 90% of all neonatal tetanus cases 
in the world in 1999 were in Africa.71  In 2010, 94% (i.e. 50/53) of African countries 
reported tetanus toxoid vaccination for pregnant women in their schedules. The 
remaining three countries instead had Td (i.e. tetanus toxoid plus reduced strength 
diphtheria vaccine) for adolescents and women of child bearing age on their schedules. 
The latter include Algeria (which gives Td at 11-13 and 16-18 years of age), Egypt (Td at 
6 and 10 years), and Tunisia (where Td is given at ages 1, 7, 12, 18 years, and women of 
childbearing age).24  According to WHO and UNICEF estimates of immunisation 
coverage, 60% of African countries had achieved at least 80% national coverage with two 
or more doses of tetanus toxoid in pregnant women by 2010; a significant improvement 
from 17% in 2000.24  In 2005, 20(38%) African countries reported validation of neonatal 
tetanus elimination (i.e. attained an incidence of less than 1 case of neonatal tetanus per 
1000 live births in every district). By 2010, the number of countries with validated 
neonatal tetanus elimination had increased to 27 (51%) of the 53 countries on the Africa 
continent.24 
 
2.7. Introduction of new and under-utilised vaccines 
The term “under-utilised vaccines” is used to refer to vaccines that have been available 
for decades in high-income countries but are not yet widely available in low and middle-
income countries; such as Hepatitis B (HepB), Haemophilus influenzae type b (Hib), and 
yellow fever vaccines.16-20 The “under-utilised vaccine” phenomenom is illustrated in 
Figure 5, using the Hib vaccine as an example. On the other hand, the term “new 
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rotavirus, and meningococcal group A conjugate vaccines.4, 5, 11-15 The last decade saw 
significant progress in the introduction of new and under-utilised vaccines into EPI 
programmes in Africa, mainly with support from GAVI.26 Most African countries are 
eligible for various forms of support from GAVI, including support for the introduction of 
new and under-utilised vaccines.26  
The HepB vaccine was first licensed in the United States of America (USA) in 1981. 
However in 2000, nearly 20 years later, only eight African countries had introduced the 
HepB vaccine into their EPI programmes. Conversely, by 2005, 70%(37/53) of African 
countries had introduced the HepB vaccine in their EPI schedules; mostly with GAVI 
support.24 In addition, significant improvements (p=0.0004) were observed by 2010, with 
96% (51/53) of countries having introduced the vaccine in their EPI schedules. Only two 
African countries (Equatorial Guinea and Somalia) did not report the HepB vaccine in 
their EPI schedule in 2010. 24  
 
Figure 5: Introduction of Hib vaccine in high and low-income countries 
 
Source: GAVI (http://www.gavialliance.org/library/news/roi/2010/hib-initiative--a-gavi-success-story/) 
 
The Hib vaccine was first licensed in the USA in 1985. Very few African countries had 
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by 2005, 14(26%) African countries reported Hib vaccine inclusion in their EPI schedules. 
By 2010, the number had increased to 45(85%) African countries with Hib vaccine in 
national EPI schedules.24 Figure 5 shows the delay between introduction of the Hib 
vaccine in high-income countries and low-income countries. The Gambia introduced the 
vaccine in 1997 (following a donation from the manufacturer), 11 years after the first high-
income country (Canada) introduced the vaccine into routine immunisation. After The 
Gambia introduced the Hib vaccine, there was another long delay which was only broken 
when GAVI launched the multi-million dollar Hib Initiative in 2005; to catalyse Hib vaccine 
introduction in low-income countries. In most African countries HepB and Hib vaccines 
were introduced as the combined pentavalent vaccine, DTP-HepB-Hib. 
Pneumonia and diarrhoea are the leading causes of death in children under five in Africa, 
and new vaccines against these major child killers have become available in the last five 
years. These vaccines are very costly and, without external support, are largely 
unaffordable by most African countries. Ten percent (5/53) of African countries had the 
pneumococcal conjugate vaccine in their EPI schedule by 2010, and an additional 16 
countries plan to introduce this vaccine by 2013; mostly with GAVI support.24, 26 Only two 
countries (South Africa and Morocco) had introduced the rotavirus vaccine into their EPI 
schedules by 2010. In 2011 Sudan became the first GAVI-eligible African country to 
introduce routine nationwide rotavirus vaccination, followed by Ghana in 2012; and nine 
other countries are planning to introduce the vaccine by 2013.24  
Epidemic meningitis is a serious public health problem among the 25 countries in the 
“African Meningitis Belt”, which extends from Senegal on the shores of the Atlantic Ocean 
to Eritrea along the Red Sea (Figure 6). About half a million people living in this region 
are at risk of epidemic meningitis each year. In 1996, there was a particularly devastating 
meningitis outbreak, which caused more than 250,000 cases and 25,000 deaths; mainly 
due to Neisseria meningitides group A (Men A). In 2001, a public-private partnership 
called the Meningitis Vaccine Project (MVP) was created with the goal of eliminating 
meningococcal epidemics in Africa.14, 15 The key partners were the Program for 
Appropriate Technology in Health (PATH), WHO, and the Serum Institute of India 
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developed an affordable Men A conjugate vaccine. Within two years of licensing the Men 
A vaccine, 10 countries (Benin, Burkina Faso, Cameroon, Chad, Ghana, Mali, Niger, 
Nigeria, Senegal, and Sudan) have already received GAVI support to introduce the 
vaccine.14, 15, 26   
 
Figure 6: The African Meningitis Belt 
 
Source: Meningitis Vaccine Project (http://www.meningvax.org/epidemics-africa.php)  
 
2.8. Role of the private sector in provision of immunisation services 
In African countries, there is paucity of data on the role of the private sector in the 
provision of immunisation services.72-74 The little available information indicates that the 
private not for-profit health sector plays an important role in the provision of immunisation 
services in Africa, while for-profit healthcare providers play a relatively small role. The 
proportion of total national immunisation services given by private for-profit healthcare 
providers was 0.05-3% in Zimbabwe in 1998, 0.7% in Ethiopia in 2006, 5% in Morocco in 
1998, and 10% in Mauritania in 2003; higher in urban than in rural areas.72 Data on the 
proportion of total immunisation services provided by NGOs were only available for two 
African countries (Kenya and Ghana). The available data show the proportion of total 
immunisation services provided by private not-for-profit providers to be 40% in Ghana 
and 45-60% in some north and north-eastern districts of Kenya in 2006. It is suggested 
though undocumented that not-for-profit organisations are providing a significant share of 
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as the Democratic Republic of Congo, Sierra Leone, and Somalia. Data from facility 
surveys in five countries indicate that a majority of NGO health facilities offer 
immunisation services, while the proportion of private for-profit facilities offering 
immunisation varies widely, from 25% in Ghana to 81% in Kenya and Uganda.72 
 
2.9. Implications of the findings of Chapter Two 
The strength of this chapter lies in our adherence to the standardised guidelines on the 
conduct and reporting of systematic reviews. We conducted comprehensive searches of 
both peer-reviewed and grey literature, without limiting the searches to a specific 
language. We assessed study eligibility using pre-defined inclusion criteria and extracted 
data in duplicate, resolving differences by consensus. The major weakness of our review 
relates to inherent shortcomings in the primary data included. African countries belong to 
two independent WHO regions; with North African countries belonging to the WHO 
Eastern Mediterranean Region (EMRO) and sub-Saharan Africa to the WHO African 
Region (AFRO). At times the two regions have different epidemiological profiles for 
various diseases and thus have different disease control priorities; the consequence 
being that comparable data were not always available for countries of both regions. 
These reasons notwithstanding, we believe that this chapter provides a comprehensive 
picture of childhood immunisation programmes on the African continent. 
It is estimated that 1.5 million children died globally in 2010 from vaccine-preventable 
diseases for which effective vaccines exist, including pneumonia and diarrhoea.75 
Approximately 20 million children did not receive the full series of three doses of the DTP 
vaccine worldwide in 2010, with more than one-third of these children living in Africa.33 
Even with the majority of African countries eligible for GAVI support, many are not on 
track with regards to meeting their GIVS and MDGs targets by 2015.42, 75, 76 Although 
many countries have introduced HepB and Hib vaccines, the majority have not yet 
introduced pneumococcal conjugate and rotavirus vaccines, and may not do so by 
2015.24, 26 This continued failure to meet agreed targets suggests that general and 
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been fully identified, understood and/or addressed effectively.77 While Africa has made 
remarkable improvements in immunisation services, this agenda remains largely 
unfinished with large numbers of African children remaining unreached, unimmunised, 
and still dying from vaccine-preventable diseases. 
We believe that in order for Africa to take advantage of the new decade of vaccines and 
extend the full benefits of immunisation to its citizens by 2020 and beyond, a critical 
assessment would be a basic step. The Decade of Vaccines Collaboration has just 
coordinated the development of yet another global immunisation strategy, the Global 
Vaccine Action Plan (GVAP), which is guided by six principles; country ownership, shared 
responsibility and partnership, equity, integration, sustainability, and innovation.32 While 
these global initiatives offer generalised strategies for attaining outlined EPI goals, it is 
absolutely necessary for complementary evidence-informed African approaches.21, 37, 38 
Therefore, locally-relevant research is needed to ensure the effectiveness, efficiency, and 
equity of childhood immunisation policies in Africa. This PhD project has hopefully added 
to the valuable body of knowledge, which is needed by African countries to attain the 
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CHAPTER 3:  Determinants of childhood immunisation research 
productivity in Africa  
 
3.1. About this chapter 
In this chapter we assess Africa’s contribution to the global immunisation research output. 
In addition, we examine whether childhood immunisation research productivity is 
associated with childhood immunisation coverage in Africa. A descriptive analysis of 
study types, quality, and outcomes is beyond the scope of bibliometric analyses, 
including the present study; and we have not provided such data in this chapter. 
 
3.2. Introduction 
During the past four decades national EPI programmes in Africa have developed or 
adapted and implemented a broad range of strategies and activities aimed at bringing 
services closer to the targeted community, increasing demand for immunisation services, 
reaching previously unreached children, and improving immunisation data quality.3, 7, 28, 30, 
47 Through these efforts, the mean proportion of annual birth cohort that received a full 
series of three doses of the diphtheria, tetanus, and pertussis vaccine (DTP3) reached 
77% in sub-Saharan Africa in 2010.33, 76 Ideally, the development or adaptation and 
implementation of EPI improvement strategies should be informed by the best available 
local evidence.78, 79 The increase in childhood immunisation coverage in Africa over the 
last four decades would therefore be expected to have been accompanied by a similar 
growth in published childhood immunisation research literature from the continent.  
Research publications have an important role in the scientific process providing a key 
linkage between knowledge generation, uptake, and use.37, 39, 80 For long, bibliometrics 
have been the method of choice for quantitative assessments of academic research at 
international, national, institutional, and individual levels.81-84 Bibliometric analysis is also 
a feasible tool to comprehensively recognise the research advances in the past and 
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factors related to variation in immunisation research productivity have not been 
examined; although bibliometric studies with data on Africa exist in other disciplines.82-96 
Therefore, this study aims to fill some of the gaps in existing research by providing 
insights into the history and growth of childhood immunisation research in Africa. We 
hypothesised that research productivity influences immunisation coverage in Africa.    
 
3.3. Methods 
3.3.1. Data collection 
We searched the PubMed database in November 2011 in order to obtain the childhood 
immunisation research volume of each African country from the inception of the EPI in 
1974 to 31 December 2010. We used childhood immunisation articles indexed in PubMed 
as a surrogate for total childhood immunisation research productivity. Articles originating 
from each country, published between 1974 and 2010 were generated by selecting the 
advanced-search option and then selecting the "publication date" field. Next, the 
"affiliation" field was searched for each country. The names of the countries were imputed 
in their different possible forms; for example, Cameroon and Cameroun for Cameroon, 
and Côte d'Ivoire and Ivory Coast for Côte d'Ivoire. Some names of countries are also 
names of parts of other countries; for example, Benin and Niger are names of places in 
Nigeria. To avoid errors arising from this, appropriate commands were used [i.e. (Niger 
[AD] NOT Nigeria)]. We then combined this with childhood immunisation Medical Subject 
Headings (Mesh): ("Immunization"[Mesh] OR "Vaccination"[Mesh] OR "Immunization, 
Secondary"[Mesh] OR "Immunization Programs"[Mesh] OR "Immunization 
Schedule"[Mesh] OR "Immunization, Passive"[Mesh] OR "Mass Vaccination"[Mesh]) AND 
("Infant, Newborn"[Mesh] OR "Infant"[Mesh] OR "Child, Preschool" [Mesh]).  
The 2010 data on DTP3 coverage, adult literacy rate, gross domestic product (GDP), 
public expenditure on education (as a percentage of GDP), human development index, 
research and development expenditure (using purchasing power parity), physicians (per 
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percentage of GDP) were obtained from the reports published by the WHO24 and World 
Bank.97 
 
3.3.2. Statistical analyses 
We calculated the ratios of the number of publications from countries to their population, 
GDP, and health expenditure in order to allow weighted comparisons. We used 
Pearson’s correlation analysis to examine the association between DTP3 coverage, 
GDP, health expenditure, and research productivity. Factors associated with variation in 
childhood immunisation research productivity were explored using univariable and 
multivariable negative binomial regression models.  
We used negative binomial regression, a variant of the Poisson-based regression model 
for count data, because of statistically significant variability in the number of indexed 
articles than might be expected (i.e. overdispersion). Negative binomial regression 
models have been shown to employ a more robust method to fit count data in the 
presence of overdispersion than the Poisson regression model itself.  Appendix 1 
provides details on the model fit statistics and model comparisons. Univariable negative 
binomial regression analyses were used to investigate the bivariate relationship between 
each country-level factor (listed above) and total research productivity. Multivariable 
negative binomial regression analyses were carried out to determine which country-level 
factors were independently associated with total research productivity. Only factors 
significant at the univariable level were included in the multivariable model. Results were 
presented as incidence rate ratios (IRR) with 95% confidence intervals (CIs) and 
percentage change. For correlation analysis and negative binomial regression, country-
level indicators were log transformed to linearise these associations. All tests were two-
sided and statistical significance was defined at the 5% alpha level. Data were processed 
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3.4. Results 
A total of 1641 articles on childhood immunisation indexed by PubMed between 1974 and 
2010 are described in this study. The summary statistics for all country-level factors 
included in this study are shown in Table 3.  The percentage of children that received 
DTP3 based on WHO/UNICEF 2010 estimates46 ranged from as low as 33% in 
Equatorial Guinea to 99% in Cape Verde, Eritrea, Morocco, Seychelles and Mauritius. 
The median adult literacy was 66% (range 26.2% to 93.0%). The median number of 
physicians per 100,000 population was 31 (range 2 to 243). 
 
Table 3: Descriptive statistics of selected country-level variables 
 
Variable Median  Range 
DTP3 coverage (%)  81.2 33.0 to 99.0 
Gross domestic product (USD billions) 27.9 0.2 to 282.8 
Adult literacy rate (%) 66.0 26.2 to 93.0 
Physicians per 100,000 population 31.1 2.0 to 243.0 
Total expenditure on health (% of GDP) 6.1 2.0 to 13.0 
Private expenditure on health (% of GDP) 3.2 1.0 to 12.0 
R&D expenditure (PPP, USD millions) 129.6 0.0 to 2494.0 
Human development index 0.5 0.3 to 0.8 
USD, United States Dollar; R&D, Research and development; PPP, purchasing power parity 
 
The number of childhood immunisation articles indexed in PubMed from each country is 
shown in Table 4. Africa's publication output trends show that its contribution to global 
childhood immunisation publications has been low during the period 1974-2010. The 
percentage share of global childhood immunisation research output increased from 6.6% 
in 1974-1980 to 9.6% in 2001-2010. The median number of articles was 16 (range 1 to 
346). Figure 7   shows the number of articles broken by quartiles. Three countries (South 
Africa, Nigeria and The Gambia) are in the highest quartile with more than 100 articles. 
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quartile (i.e. 10 to 49 articles). Twenty countries with less than ten articles belong to the 
lowest quartile.  
 
Table 4: Trends in African childhood immunisation articles per country as indexed 
by PubMed (1974 - 2010) 
 Publications 
Country 1974-1980 1981-1990 1991-2000 2001-2010 1974-2010 
South Africa 21 65 153 107 346 
Nigeria 15 30 42 67 154 
Gambia 1 20 43 40 104 
Egypt 8 7 37 47 99 
Kenya 11 16 24 36 87 
Senegal 5 13 29 23 70 
Ghana 11 4 13 26 54 
Zimbabwe 1 14 22 9 46 
Ethiopia 2 3 20 19 44 
Uganda 6 7 10 17 40 
Burkina Faso 0 5 11 24 40 
Tanzania 1 8 9 21 39 
Malawi 0 4 12 18 34 
Sudan 1 11 11 10 33 
Zambia 1 4 7 16 28 
Democratic Republic of Congo 0 7 14 5 26 
Cameroon 6 7 5 7 25 
Mali 6 4 4 11 25 
Cote d`Ivoire 2 6 8 9 25 
Mozambique 0 8 3 13 24 
Morocco 3 3 4 12 22 
Chad 0 1 8 13 22 
Guinea-Bissau 0 3 5 13 21 
Tunisia 2 6 6 5 19 
Guinea 0 0 10 9 19 
Togo 2 3 6 7 18 
Angola 0 0 10 6 16 
Niger 1 0 6 8 15 
Madagascar 1 1 6 7 15 
Somalia 2 6 3 4 15 
Congo-Brazzaville 0 4 5 6 15 
Benin 0 1 4 8 13 
Rwanda 0 1 6 5 12 
Namibia 0 0 7 2 9 
Central African Republic 1 0 5 1 7 
Algeria 1 3 2 0 6 
Gabon 0 1 3 2 6 
Liberia 0 2 2 2 6 
 
Continued in next page … 
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Country 1974-1980 1981-1990 1991-2000 2001-2010 1974-2010 
Burundi 0 0 4 1 5 
Sierra Leone 1 1 3 0 5 
Djibouti 0 1 2 1 4 
Botswana 0 0 4 0 4 
Swaziland 0 0 3 1 4 
Eritrea 0 0 1 3 4 
Lesotho 0 0 3 0 3 
Libya 0 2 1 0 3 
Comoros 0 0 1 1 2 
Cape Verde 0 1 0 1 2 
Sao Tome and Principe 0 1 1 0 2 
Seychelles 0 0 1 0 1 
Mauritania 0 1 0 0 1 
Mauritius 0 0 1 0 1 
Equatorial Guinea 0 0 1 0 1 
Total: Africa output 112 285 601 643 1641 
Total: World output 1702 3485 5816 6679 18388 
% world research output 6.6 8.2 10.3 9.6 8.9 
 
 
Figure 7: Colour-coded map representing childhood immunisation research 
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Table 5 shows the top-ranking countries in terms of relative contribution of each country 
to the total number of articles. In absolute terms authors from the top five countries 
combined produced almost half (48%) of the total indexed articles. Authors from South 
Africa produced the highest number of articles (n=346, 21%), followed by Nigeria (n=154, 
9%) and The Gambia (n=104, 6%). As shown in Table 5, the Gambia, Guinea-Bissau, 
and Sao Tome and Principe had the highest number of publications after controlling for 
the country’s population and GDP. When controlled for total expenditure on health, the 
top three countries were South Africa, Nigeria, and Kenya. 
 
Table 5: Top 10 countries in terms of childhood immunisation research 





Population Gross domestic 
product 
Total expenditure on 
health 
1 South Africa 346 (21.1) The Gambia The Gambia South Africa 
2 Nigeria 154 (9.4) Guinea-Bissau Guinea-Bissau Nigeria 
3 The Gambia 104 (6.3) Sao Tome & Principle Sao Tome & Principle Kenya 
4 Egypt 99 (6.0) Seychelles Zimbabwe Egypt 
5 Kenya 87 (5.3) South Africa Malawi The Gambia 
6 Senegal 70 (4.3) Senegal Liberia Senegal 
7 Ghana 54 (3.3) Djibouti Togo Ethiopia 
8 Zimbabwe 46 (2.8) Cape Verde Senegal Tanzania 
9 Ethiopia 44 (2.7) Gabon Burkina Faso Ghana 
10 Burkina Faso & 
Uganda 
40 (2.4) Namibia Guinea Burkina Faso 
 
The trend in total production of childhood immunisation articles in each geographical sub-
region of Africa is displayed in Figure 8, which shows that West Africa was the most 
productive sub-region during the period studied. Apart from Central Africa and Southern 
Africa which experienced a drop between 2001 and 2010, there was a continuous 
increase in the production of research articles from all African sub-regions during the 
period 1974 to 2010. The total number of articles from West Africa, for example, 
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Figure 9 shows the correlation between total research production and country’s GDP. 
There was a moderately positive and statistically significant correlation between the total 
number of published articles on childhood immunisation and the country’s GDP (r = 
0.548, p=0.000).  Similarly, there was a moderately positive and statistically significant 
correlation between each country’s research and development expenditure (r = 0.541, 
p=0.000) and the total number of articles from the country that were indexed between 
1974 and 2010 (Figure 10). Country-level factors associated with total childhood 
immunisation research productivity are shown in Table 5. In the unadjusted model, GDP, 
total expenditure on health, private expenditure on health, and research and development 
expenditure were statistically significantly associated with increased childhood 
immunisation research productivity. In the univariable analyses, immunisation coverage, 
adult literacy rate, human development index, and physician density had no significant 
association with number of immunisation articles. Only private expenditure on health 
remained statistically significant in the adjusted multivariable model, when all factors were 
controlled for statistically. A unit increase in private expenditure on health increased the 
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Figure 8: Trends in Africa sub-regional childhood immunisation articles output 
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Figure 9: Scatter plot showing association between total publications and 
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Figure 10: Scatter plot showing association between total publications and 
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Table 6: Factors associated with childhood immunisation research productivity 
identified by negative binomial regression models 
 
 Univariable Multivariable 
Variable IRR (95% CI) p-value IRR (95% CI) p-value 
DTP3 coverage 0.40 (0.07, 2.36) 0.310 not included  
Gross domestic product (US dollar) 1.44 (1.24, 1.66) 0.000 1.27 (0.74, 2.18) 0.380 
Adult literacy rate 1.16 (0.42, 3.18) 0.771 not included  
Physicians per 100,000 population 1.24 (0.96, 1.60) 0.096 not included  
Total expenditure on health 3.21 (1.09, 9.41) 0.034 0.66 (0.14, 3.11) 0.596 
Private expenditure on health 2.77 (1.61, 4.79) <0.0001 2.82 (1.29, 6.19) 0.010 
Research and development expenditure 1.44 (1.22, 1.72) <0.0001 1.09 (0.61, 1.94) 0.782 
Human development index 2.37 (0.59, 9.51) 0.224 not included  
IRR – incidence rate ratio, CI confidence interval 
 
3.5. Implication of the findings of Chapter Three 
We found that childhood immunisation research productivity in Africa is highly skewed. 
South Africa, Nigeria, The Gambia, Egypt, and Kenya jointly account for almost half of 
the articles on childhood immunisation indexed in PubMed between 1974 and 2010. 
There was a significant increase in the number of publications from all African sub-
regions between 1974 and 2010. However, Africa's contribution to global childhood 
immunisation publications has been minimal during the period studied. The Gambia, 
Guinea-Bissau, Sao Tome and Principe, Zimbabwe, and Malawi had better records 
when the total research productivity was adjusted for gross domestic product. When 
controlled for total expenditure on health, South Africa, Nigeria, Kenya, Egypt, and The 
Gambia were the most productive. Multiple medical schools and research institutions in 
South Africa, Nigeria, and Egypt may account for the large number of publications from 
these three countries. Similarly, the presence of the British Medical Research Council, 
the Kenyan Medical Research Institute, and a Danish research group (Bandim Health 
Project) may be the drivers of publications from The Gambia, Kenya, and Guinea-
Bissau respectively.  Even in many African countries without internationally supported 
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Although North-South collaboration is highly positive, it is legitimate to question the 
ownership of research in most of these countries mentioned. 
The most significant predictor of research productivity in our study was found to be 
private health expenditure, which may be a proxy for the economic development status 
of a country. Rahman and Fukui studied factors related to worldwide variation in 
biomedical research productivity, and found that gross national product per capita and 
research and development expenditure were significant determinants of biomedical 
research productivity.98, 99 We did not find these factors to be significant predictors of 
immunisation research productivity in Africa. However, if we consider private health 
expenditure to be a surrogate measure of the economic development of a country, then 
our results are consistent with those of Rahman and others that the better the economic 
ranking of a country the higher the quantity of its research productivity.82, 96, 98-100 In 
addition, we confirm the findings of other authors that the contribution of authors from 
Africa to the global biomedical research literature is minimal.85, 86, 89, 92, 96 This meagre 
biomedical research literature from the continent is dominated by non-communicable 
disease research.90  
Locally-relevant health research is needed to ensure the effectiveness, efficiency, and 
equity of immunisation policies in Africa.37, 54 In general, health research helps to 
answer questions, to generate the evidence required to guide policy, and to identify new 
tools. A descriptive analysis of study types, quality, and outcomes was beyond the 
scope of our bibliometric analysis.  
PubMed has been widely used for bibliometric analysis, but it is important to note that 
the database is dominated by English-language journals; therefore possibly contributing 
to selection bias due to language barriers. Therefore, we may have missed some 
publications from French- and Portuguese-speaking African countries. By using the 
author addresses listed in the by-lines of research articles, one can only identify 
countries and organisations where the authors were employed when the research was 
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believe that this study is a good reflection of research productivity in the field of 
childhood immunisation in Africa. 
In conclusion, this study examined almost three decades of childhood immunisation 
research production by authors from Africa. The results of the study showed that the 
five most productive countries, in terms of absolute number of publications indexed by 
PubMed from 1974 to 2010, are South Africa, Nigeria, The Gambia, Egypt, and Kenya. 
Based on the best possible estimate, the most significant determinant of immunisation 
research productivity in sub-Saharan Africa is private health expenditure, which may be 
a surrogate measure of the economic ranking of a country. The lack of association 
between research productivity and immunisation coverage may be a  indication of lack 
of interactive communication between health decision-makers, programme managers, 
and researchers; to ensure that health decisions are always informed by the best 
available research evidence. However, the lack of association may also stem from lack 
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CHAPTER 4: Determinants of low childhood immunisation 
coverage in Africa  
 
 
4.1. About this chapter 
In this chapter we describe the development, testing, and results of a model of 
childhood immunisation coverage that includes personal and family characteristics 
along with contextual characteristics defined at the community and country levels.  
 
4.2. Introduction 
As Africa continues to grapple with a range of programme and policy challenges related 
to childhood immunisation, we believe that one important element in improving the 
status quo is a comprehensive and relevant evidence base that would equip countries in 
the region to take informed actions. Without comprehensive information about the 
factors associated with failure to complete the full series of recommended vaccines, it is 
hard to plan substantial public health programmes that would improve childhood 
immunisation programmes in the continent.  
Some studies have been conducted to examine factors associated with low childhood 
immunisation coverage in Africa.101-109  Most of these studies have concentrated on 
individual-level factors 101-107 and only few have considered community-level factors. 101, 
108, 109 To the best of our knowledge, there has been no multilevel study performed to 
date that examined the separate and independent contributions of individual, 
community, and country-level factors to the low uptake of immunisation services in 
Africa. We therefore conducted this study to fill this research gap and to draw attention 
to the largely unexplored contextual factors that may be associated with low childhood 
immunisation coverage on the continent. The objective of this sub-study was therefore 
to develop and test a model of childhood immunisation which includes individual-level 
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country levels. We hypothesised that pre-specified community- and country-level factors 
are associated with childhood immunisation coverage in Africa.  
4.3. Methods 
4.3.1. Data collection 
We based this study on an analysis of existing survey data collected by the Monitoring 
and Evaluation to Assess and Use Results Demographic and Health Surveys 
(MEASURE DHS) project (www.measuredhs.com).  The Demographic and Health 
Survey (DHS) program was established by the United States Agency for International 
Development (USAID) in 1984. It was designed as a follow-up to the World Fertility 
Survey and the Contraceptive Prevalence Survey projects. The DHS project was first 
awarded in 1984 to Westinghouse Health Systems (which subsequently evolved into 
part of OCR Macro). The project has been implemented in overlapping five-year 
phases; DHS-I ran from 1984 to1990; DHS-II from 1988 to1993; and DHS-III from 1992 
to1998. In 1997, DHS was folded into the new multi-project MEASURE program as 
MEASURE DHS+. Since 1984, the project has collected standardised nationally 
representative survey data in over 90 countries110.  
In November 2011 we selected the latest DHS from any country in sub-Saharan Africa 
that was conducted since the launch of MEASURE DHS project in 1997. We chose only 
sub-Saharan Africa (as opposed to all of Africa) for these analyses because, as shown 
in Chapter 2, immunisation coverage has been consistently above 90% in all North 
African countries. The factors related to immunisation coverage are therefore bound to 
be different in such settings, and it would not have made sense to lump the two 
geographical sub-regions together. The 24 surveys included in this study were 
conducted by the MEASURE DHS between 2003 and 2010.  The surveys were 
approved by the Institutional Review Board of Macro International in Calverton in the 
United States of America and by the National Ethical Review Committees in Benin, 
Burkina Faso, Cameroon, Chad, Democratic Republic of Congo, Ethiopia, Ghana, 
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Sao Tome & Principle, Senegal, Sierra Leone, Swaziland, Uganda, Zambia, and 
Zimbabwe. All participants gave written informed consent before participation and all 
information was collected confidentially. We obtained the raw survey data and written 
consent of MEASURE DHS to use the data.  
DHS surveys are implemented by respective national institutions and Macro 
International Inc., with financial support from the USAID. Selection of the countries in 
this study was determined by availability of comparable data on childhood 
immunisation. DHS data are nationally representative, cross-sectional, household 
sample surveys with large sample sizes, typically between 5,000 and 15,000 
households. The sampling design typically involves selecting and interviewing 
separately nationally representative probability samples of women aged 15-49 years 
and men aged 15-59 years based on multi-stage cluster sampling, using strata for rural 
and urban areas and for different regions of the countries. A standardised questionnaire 
was administered by interviewers to participants in each country. The survey 
instruments (i.e. household questionnaire and women’s questionnaire) were 
comparable across countries, yielding inter-country comparable data.  We used the 
term community to describe clustering within the same geographical living environment. 
Communities were based on sharing a common primary sample unit within the DHS 
data. The sampling frame for identifying the primary sample unit in the DHS is usually 
the most recent census. Country-level data were collected from the reports published by 
the World Bank97. 
 
4.3.2. Variables 
We used the WHO definition of an “unimmunised child” as the outcome variable. 
“Unimmunised child” was defined as a binary variable that takes the value of 1 if the 
child 12-23 months old has received DTP3 and 0, otherwise. We limited the analysis to 
one randomly selected child per woman in order to minimise over-representation of 
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country is the number of children aged 0-11 months. Therefore, the immunisation 
coverage among children aged 12-23 months during a survey year corresponds to the 
immunisation coverage in the EPI cohort of the previous year for that country. This 
explains why we focused on children aged 12-23 months during the survey year. 
Our pre-specified determinant variables consisted of individual, community, and 
country-level factors. We included the following individual level factors: child’s age (in 
months),  child sex (male or female), high birth order (less than 24 months), number of 
under-five children, polygamous family, mother’s age (15-24, 25-34, or 35 years or 
older), wealth index (poorest, poorer, middle, richer, richest), mother’s and father’s 
education (no education, primary, secondary, or higher), employment status (working or 
not working), media access (access to radio, television or newspaper), and maternal 
health seeking behaviours (prenatal visits, tetanus injection during pregnancy, medical 
assistance at delivery, knowledge of oral rehydration solution, and possession of a 
health card for the child). 
We included the following community-level factors: 
 Neighbourhood poverty: percentage of households below 20% of wealth index 
 Illiteracy rate: percentage of women with no formal education in the community 
 Unemployment rate: percentage of women not working in the community 
 Media access: percentage of households with access to television, radio or 
newspaper 
 Average household size: mean number of people in each community 
 Female-headed households: percentage of households headed by women in an 
area. 
 Residential mobility:  proportion of households occupied by persons who had moved 
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 Place of residence: urban or rural, as administratively defined by each country 
 Ethnic diversity - an index of ethnic diversity was created using a formula that 
captures both the number of different groups in an area and the relative 
representation of each group 114 : 
2
1









                                      
where: 
ix =population of ethnic group i of the area,  
y = total population of the area, and  
 n = number of ethnic groups in the area 
Scores can range from 0 to approximately 1. For clarity of interpretation, each diversity 
index is multiplied by 100; the larger the index, the greater diversity there is in the area. 
If an area’s entire population belongs to one ethnic group, then an area has zero 
diversity. An area’s diversity index increases to 100 when the population is evenly 
divided into ethnic groups.  
At country-level, we included fertility rate, gross domestic product (GDP), expenditure 
on health, and adult illiteracy rate. We categorised community- and country-level 
variables into two categories (low and high) to allow for nonlinear effects and provide 
results that were more readily interpretable in the policy arena. Median values served as 
the reference group for comparison.  
We included the year the DHS was conducted as a partial control for a period trend to 
control for effects of unknown factors, which might have been introduced due to 
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4.3.3. Statistical analyses 
Multilevel logistic regression models were used to examine factors associated with 
childhood immunisation. We specified a 3-level model for the binary variable: an 
“unimmunised child” (level 1), living in a community (level 2), from a country (level 3). 
We constructed six models. The first model, an empty model, was without any 
determinant variables i.e. a simple component of variance analysis. The second model 
contained only the control variable (survey year). The third, fourth, and fifth models 
provided additional controls for individual-, community- and country-level factors 
respectively. The sixth model simultaneously controlled for survey year, individual-, 
community-, and country-level factors. 
The measures of association (fixed-effects) were reported as odds ratios (ORs) with 
their 95% confidence intervals (CIs). The measures of variation (random-effects) 
included the variance, intra-cluster correlation (ICC), and median odds ratio (MOR). The 
ICC was calculated by the linear threshold according to the formula used by Snijders 
and Bosker. 115  The MOR is a measure of unexplained cluster heterogeneity and the 
method used for calculating the MOR has been described elsewhere. 116, 117 The 
multilevel models were fitted with MLwiN 2.24. 118 The statistical significance of 
covariates were calculated using the Wald test.118 All significance tests were two-tailed 
and statistical significance was defined at the 5% alpha level. 
4.4. Results  
4.4.1. Sample characteristics   
The survey characteristics are shown in Figure 11. The DHS were conducted between 
2003 and 2010. The number of children included in the surveys ranged from 1,931 in 
Sao Tome and Principe to 28,647 in Nigeria. The age of children included in the 
analysis ranged from 12 to 23 months. The median number of children is 882 (range: 
373 to 4921). The proportion of un-immunised children ranged from as low as 4.6% in 
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Figure 11:  Description of DHS data 2003-2010 in Africa by country  
% unimmunizcd 
country year total ""'go children (95% el) 
Malawi 2010 19967 1145 • 4.63 (3.4 1, 5.85) 
Swaziland 2007 2812 491 • 5.70 (3.65 , 7.75) 
Rwanda 2008 5489 11 67 • 8.57 (6.96, 10.17) 
Ghana 2008 2992 562 • 10.68 (8.12. 13.23) 
Sao Tome & I'rincple 2009 1931 373 .. 10.99(7.82, 14.17) 
Namibia 2007 5168 899 • 13.68 ( 11.44, 15.93) 
Lesotho 2010 3999 394 ...... 15.99 ( 12.37, 19.6 1) 
Kenya 2009 6079 1091 • 18.70 ( 16.38, 21.0 1) 
Senegal 2005 10944 721 .. 22.88 ( 19.82, 25 .95) 
Madagascar 2009 12448 1072 • 28.73 (26.02. 3 1.44) 
Mali 2006 14238 2520 • 30.40 (28.60, 32.19) 
Benin 2006 16075 3010 • 3 1.93 (30.26, 33.59) 
Cmneroon 2004 8125 785 .. 32.36 (29.08. 35.63) 
Sierra Leone 2008 5631 S3S ...... 35.14 (3 1.09, 39.19) 
Zimbabwe 2006 5246 957 .. 35.63 (32.60, 38.67) 
Bud cina l;aso 2003 10645 18 19 • 38.15 (35.92, 40.39) 
Guinea 2005 6364 S73 ...... 44.33 (40.26, 48.40) 
Cougo DR 2007 8992 835 ...... 48.98 (45.59, 52.37) 
Niger 2006 9193 823 ...... 52.13 (48.7 1, 55.54) 
Ethiopia 2005 9861 865 .. 64.74 (6 1.56, 67.92) 
Nigeria 2008 28647 492 1 • 65.54 (64.2 1, 66.86) 
elmd 2004 5635 901 .. 68.81 (65.79,71.84) 
Zambia 2007 6401 1245 • 79.76 (77.53, 81.99) 
Ug3mb 2006 8369 550 .. 84.18 (81 . 13 , 87.23) 
1 1 1 1 1 
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4.4.2. Measures of variation (random effects) 
As shown in Table 6, Model 1 (the null model), there was a significant variation in the 
odds of being an “unimmunised child” across the countries ( =1.031, p<.001) and 
across the communities ( =0.554, p<.01). According to the intra-country and intra-
community correlation coefficient implied by the estimated intercept component 
variance, 21% and 32% of the variance in the “unimmunised child” could be 
attributed to the country- and community-level factors respectively. The variations 
across communities and countries remained statistically significant, even after 
controlling for all factors in model 6.  
Results from the MOR also confirmed evidence of community and country contextual 
phenomena shaping the odds of being an “unimmunised child”. The high MOR (3.31) 
in Model 1 between children with a higher and lower propensity of being 
“unimmunised” in a community suggests that the community heterogeneity is 
substantial. When all factors were included in the model, the unexplained 
heterogeneity between communities remained substantial with an MOR of 2.29. 
 
4.4.3. Measures of association (fixed effects) 
The results of fitting the model including only the control variable (survey) is shown in 
Table 6 (model 2). There was no statistically significant association between the 
survey year and the odds of being unimmunised. The results of fitting the model 
including the control variable (survey) and individual-level factors is shown in Table 6 
(model 3). For every one month increase in a child’s age, the odds of being 
unimmunised decreased by 3% (odds ratio [OR] 0.97, 95% confidence interval [CI] 
0.96 to 0.98). Compared with children of older mothers (i.e. 35 years or older), 
children of younger mothers were more likely to be unimmunised (OR 1.22, 95% CI 
1.09 to 1.36). Similarly, children from the poorest households were more likely to be 
unimmunised than their counterparts from the richest households. Children born to 
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with no formal education were more likely to be unimmunised than those born to 
parents with secondary or higher education respectively. Children whose mothers 
were unemployed were more likely to be unimmunised than those whose mothers 
were employed (OR 1.09, 95% CI 1.01 to 1.17). Maternal access to media reduced 
the odds of a child being unimmunised by 6% (OR 0.94, 95% CI 0.94 to 0.98). 
Mothers with health seeking behaviours were 46% less likely to have unimmunised 
children (OR 0.54, 95% CI 0.53 to 0.56).  
The results of fitting the model including the control variable (survey) and community-
level factors is shown in Table 6 (model 4). Children from urban areas were less 
likely to be unimmunised than those from rural areas (OR 0.84, 95% CI 0.77 to 0.92). 
Children from communities with high neighbourhood illiteracy (OR 1.62, 95% CI 1.50 
to 1.74), poverty (OR 1.24, 95% CI 1.15 to 1.34), and unemployment (OR 1.14, 95% 
CI 1.07 to 1.22) rates were 62%, 24%,  and 14% more likely to be unimmunised. 
Children from communities with high media access (OR 0.71, 95% CI 0.66 to 0.77) 
and female-headed households (OR 0.88, 95% CI 0.82 to 0.93) were 29% and 12% 
less likely to be unimmunised.  
The results of fitting the model including the control variable (survey) and country-
level factors is shown in Table 6 (model 5). Children from countries with higher 
fertility rates were more than four times more likely to be unimmunised. 
The result of the full model including all co-variables is shown in Table 6 (model 6). 
With all factors controlled for statistically, the following factors remained significantly 
associated with the odds of being unimmunised: individual-level (child’s age, 
polygamous family, mother’s age, wealth index, mother’s and father’s education, 
media access, and maternal health seeking behaviours); community-level (place of 
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Table 7: Factors associated with unimmunised children in sub-Saharan Africa, identified by multilevel logistic 
regression 
 
 Model 1a Model 2b Model 3c Model 4d Model 5e Model 6f 
Factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
       
Control variable       
Survey year       
2003  1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
2004   1.70 (0.21 - 13.89) 1.84 (0.26 - 12.80) 1.82 (0.20 - 16.58) 0.42 (0.04 - 4.74) 0.31 (0.03 - 2.98) 
2005   1.26 (0.17 - 9.13) 1.11 (0.18 - 6.90) 1.25 (0.16 - 10.04) 1.47 (0.19 - 11.38) 0.98 (0.15 - 6.46) 
2006   1.44 (0.22 - 9.39) 1.88 (0.33 - 10.67) 1.53 (0.21 - 11.05) 0.53 (0.07 - 4.15) 0.50 (0.08 - 3.10) 
2007   0.96 (0.14 - 6.57) 1.73 (0.29 - 10.19) 0.98 (0.13 - 7.34) 0.59 (0.07 - 5.24) 0.54 (0.08 - 3.81) 
2008   0.67 (0.10 - 4.54) 1.02 (0.16 - 6.33) 0.66 (0.09 - 4.99) 1.53 (0.15 - 15.87) 1.04 (0.13 - 8.38) 
2009   0.39 (0.05 - 2.85) 0.61 (0.10 - 3.79) 0.39 (0.05 - 3.10) 0.22 (0.03 - 1.64) 0.24 (0.04 - 1.42) 
2010   0.18 (0.02 - 1.48) 0.29 (0.04 - 2.05) 0.20 (0.02 - 1.81) 0.19 (0.02 - 1.92) 0.17 (0.02 - 1.36) 
       
Child’s age     0.97 (0.96 - 0.98)***     0.97 (0.96 - 0.98)*** 
Male (vs. female)     1.01 (0.95 - 1.08)     1.01 (0.95 - 1.07) 
High birth order     1.05 (0.96 - 1.14)     1.05 (0.97 - 1.14) 
Under-5 children     1.02 (0.99 - 1.05)     1.02 (0.99 - 1.05) 
Polygamous family     1.08 (1.01 - 1.16)     1.08 (1.01 - 1.16)* 
Mother’s age       
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 Model 1a Model 2b Model 3c Model 4d Model 5e Model 6f 
Factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
25-34     1.07 (0.98 - 1.16)     1.05 (0.96 - 1.15) 
35 or older   1 (reference)   1 (reference) 
Wealth index       
Poorest     1.34 (1.17 - 1.52)***     1.36 (1.17 - 1.59)*** 
Poorer     1.25 (1.11 - 1.42)***     1.30 (1.13 - 1.51)*** 
Middle     1.14 (1.01 - 1.29)*     1.21 (1.06 - 1.39)** 
Richer     1.09 (0.97 - 1.23)     1.15 (1.02 - 1.30)* 
Richest   1 (reference)   1 (reference) 
Mother’s education       
No education     1.48 (1.31 - 1.67)***     1.35 (1.18 - 1.53)*** 
Primary     1.28 (1.15 - 1.43)***     1.26 (1.12 - 1.40)*** 
Secondary or higher   1 (reference)   1 (reference) 
Father’s education       
No education     1.19 (1.07 - 1.31)**     1.13 (1.02 - 1.26)* 
Primary     0.99 (0.90 - 1.09)     1.00 (0.91 - 1.10) 
Secondary or higher   1 (reference)   1 (reference) 
Not working     1.09 (1.01 - 1.17)*     1.06 (0.98 - 1.14) 
Media access     0.94 (0.90 - 0.98)**     0.94 (0.90 - 0.99)* 
Health seeking beh.     0.54 (0.53 - 0.56)***     0.56 (0.54 - 0.58)*** 
COMMUNITY-LEVEL       
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 Model 1a Model 2b Model 3c Model 4d Model 5e Model 6f 
Factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Ethnic diversity       1.05 (0.97 - 1.13)   1.08 (1.00 - 1.16) 
Neigh. Poverty       1.24 (1.15 - 1.34)***   1.03 (0.94 - 1.13) 
% female-headed       0.88 (0.82 - 0.93)***   0.95 (0.89 - 1.02) 
Residential instability       0.98 (0.92 - 1.05)   1.02 (0.95 - 1.09) 
Illiteracy rate       1.62 (1.50 - 1.74)***   1.13 (1.05 - 1.23)** 
Unemployment rate       1.14 (1.07 - 1.22)***   1.03 (0.96 - 1.11) 
% media access       0.71 (0.66 - 0.77)***   0.94 (0.86 - 1.02) 
Av. Household size       1.07 (1.00 - 1.14)   1.02 (0.95 - 1.09) 
COUNTRY-LEVEL       
Fertility rate         4.47 (1.19 - 16.74)* 4.43 (1.04 - 18.92)* 
GDP (US$)         1.75 (0.48 - 6.31) 1.44 (0.33 - 6.37) 
Health expenditure         0.37 (0.11 - 1.23) 0.62 (0.19 - 2.03) 
Literacy rate         2.25 (0.71 - 7.07) 2.60 (0.90 - 7.50) 
              
RANDOM PART             
Variance              
Country 1.031 (0.300) 0.761 (0.222) 0.648 (0.194) 0.842 (0.246) 0.631 (0.185) 0.492 (0.148) 
Community 0.554 (0.029) 0.663 (0.032) 0.275 (0.029) 0.440 (0.028) 0.751 (0.035) 0.267 (0.028) 
ICC (%)       
Country 21.1 16.1 15.4 18.4 13.5 12.1 
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 Model 1a Model 2b Model 3c Model 4d Model 5e Model 6f 
Factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
MOR       
Country 2.62 2.29 2.15 2.39 2.13 1.95 
Community 3.31 3.11 2.49 2.93 3.06 2.89 
* p<0.01, **p<0.001 ***p<0.0001; ICC – intra-cluster correlation; MOR – median odds ratio; OR- odds ratio; CI – confidence interval 
a
Model 1 is null model, baseline model without any determinant variable 
b
Model 2 is adjusted for control variable alone  
c
Model 3 is additionally adjusted for control variable and individual-level factors  
d
Model 4 is additionally adjusted for control variable and community-level factors  
e
Model 5 is additionally adjusted for control variable and country-level factors  
f

















4.5. Implication of the findings of Chapter Four 
We expanded upon previous literature by providing evidence of contextual factors, 
measured at community and country levels, associated with childhood immunisation 
coverage. In particular, the study provided evidence that unimmunised children were 
more likely to be from communities with high illiteracy rates and countries with high 
fertility rates. Contrary to our expectation, we found that children from urban areas 
were more likely to be unimmunised than those from rural areas. At individual level, 
children from poorest households, uneducated parents, mothers with no access to 
media, and mothers with low health seeking behaviours were more likely to be 
unimmunised. In addition, we found evidence of clustering effects of non-
immunisation at both community and country levels, such that children from the same 
communities tended to have similar immunisation status. This suggests that children 
in the same neighbourhood are subject to common contextual influences;119 thus, 
providing evidence of contextual phenomenon shaping children’s risk of being 
unimmunised. 
An evidence-informed approach to improving childhood immunisation programmes in 
Africa and, consequently, reducing child mortality in the continent demands first an 
understanding of why programmes have failed to reach their optimum potential. 
Secondly, appropriate strategies should be employed to address the identified short 
comings of immunisation programmes. Without such a systematic approach, 
significant proportions of scarce resources will continue to be squandered on 
ineffective interventions; and millions of children will continue to die from easily 














Our multilevel analysis revealed that low parental and community knowledge of 
immunisation and/or lack of access to information on childhood immunisation could 
be an important contributor to the high burden of unimmunised children in sub-
Saharan Africa. This assertion is supported by the finding of significant reductions in 
the number of unimmunised children among parents and communities with access to 
mass media. In addition, unimmunised children were found to cluster in communities, 
increasing the risk of disease outbreaks. It is therefore important to identify effective 
interventions to enable parents and communities to understand the meaning and 
relevance of vaccination to their health and the health of their families and 
communities. However, at present, there is a paucity of synthesised research 
evidence on effective interventions for improving childhood immunisation 
programmes in low and middle-income settings such as sub-Saharan Africa.74, 120-123 
The few currently available systematic reviews relevant to childhood immunisation 
programmes in sub-Saharan Africa show that parent reminder and recall systems124 
and mass media interventions125 have the potential to increase immunisation 
coverage. Verbal, video, or provider-delivered communication tools may also 
increase parents’ understanding, especially if the tools are structured, tailored and 
interactive126. In addition, interventions to promote interaction between the 
community and health services may build trust and generate awareness and 
understanding of vaccination issues among parents.121 Interventions of this nature 
embrace collective decision making and community involvement in planning, 
programme delivery, advocacy, and/or governance of immunisation programmes. 














Furthermore, the finding that women with health seeking behaviours are more likely 
to have their children immunised might be an indication that integration is an effective 
strategy in immunisation programmes.3  
The main strengths of this chapter include having a pre-defined hypothesis and 
selection of determinant variables, conducting multi-level modeling, and having 
representative data across many countries. The only limitation was our reliance on 
cross-sectional dataset.  
In conclusion, we found that individual and contextual factors were associated with 
childhood immunisation, suggesting that public health programmes designed to 
improve childhood immunisation coverage in sub-Saharan Africa should address 
people and the communities and societies in which they live. Synthesis of existing 
immunisation barriers and the evidence on effective interventions to address these 
barriers should be a systematic and integral component of childhood immunisation 
















CHAPTER 5: Strategies for improving childhood immunisation 
coverage in Africa 
 
 
5.1. About this chapter 
In this chapter we summarised the current best evidence from systematic reviews 
and randomised controlled trials of interventions for improving childhood 
immunisation coverage. In addition, we discussed the relevance of the evidence to 
childhood immunisation programmes in Africa. 
 
5.2. Introduction 
The EPI faces a number of challenges in Africa.70, 127-129 The vaccination coverage is 
low,77, 130 epidemics of vaccine-preventable diseases are frequent,10, 19, 60, 68, 70, 129, 131 
healthcare infrastructure is weak, skilled human resources are scarce, and 
community knowledge of immunisation is low.127 Making well-informed decisions 
about how best to achieve high and equitable immunisation coverage in Africa will 
depend partly on African policymakers accessing the best scientific evidence about 
what interventions work, and integrating this evidence into national health systems in 
the continent37. Interventions for improving immunisation coverage can be aimed at 
increasing demand for immunisation services by mothers and their children (demand-
side strategies), or aimed at increasing the availability of immunisation services (i.e. 
supply-side strategies).78 Demand-side (or patient-oriented or consumer-oriented) 
interventions address barriers to vaccination associated with parental knowledge and 
understanding, attitudes, beliefs and behaviour as well as socio-economic factors of 
households.77 Supply-side (or provider-oriented) interventions refer to strategies such 
as the availability of effective vaccines, technologies to support their application, and 
healthcare workers to deliver services.77 In order to ensure evidence-informed 
selection and implementation of effective healthcare interventions37 that would 














life-saving vaccines, we conducted a comprehensive search of the peer-reviewed 
literature, identified, and synthesised systematic reviews and randomised controlled 
trials of strategies for improving childhood immunisation programmes.   
We chose systematic reviews and randomised controlled trials because they occupy 
the two top spots in the hierarchy of evidence on the effects of interventions. A 
randomised controlled trial is the most rigorous way of determining whether a cause-
effect relationship exists between an intervention and an outcome, and of assessing 
the cost-effectiveness of interventions. A systematic review of two or more 
randomised controlled trials provides even better evidence than a single randomised 
controlled trial. A systematic review is a summary of evidence in which bias and 
chance have been reduced by the systematic identification, appraisal, and synthesis 
of all relevant studies on a specific topic according to a transparent and 
predetermined method. Systematic reviews have an inherent ability to minimise 
systematic and random errors in the assessment of existing research as well as 
provide a means for researchers and policymakers to access all existing evidence on 
key questions in a thoughtful manner.37  
 
5.3. Methods 
5.3.1. Search and selection of systematic reviews 
Between 20 and 30 March 2012 we searched PubMed, the Health Systems Evidence 
database, the Cochrane Database of Systematic Reviews, and the Database of 
Abstracts of Reviews of Effectiveness; using the search strategy shown in Appendix 
2. We screened the search results, selected relevant systematic reviews, and 
assessed the quality of the selected reviews (using a revised version of the AMSTAR 
tool132). In particular, we assessed whether the review authors: 
1. reported the study selection criteria;  
2. conducted a literature search that was comprehensive enough to avoid 














3. undertook duplicate study selection and data extraction;  
4. used reliable criteria to assess the risk of bias in included studies;  
5. reported the characteristics of included studies appropriately; and  
6. combined data from included studies using reliable methods.  
Based on these criteria, we concluded whether the review was reliable or not.  
 
5.3.2. Assessment of the quality of evidence from systematic reviews 
The GRADE approach133, 134 was used to assess the quality of the evidence for the 
effectiveness of the interventions reported in the reviews. This method results in an 
assessment of the quality of a body of evidence as high, moderate, low, or very low. 
High quality evidence implies that “further research is very unlikely to change our 
confidence in the estimate of effect”. Moderate quality evidence means that “further 
research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate”. Evidence is considered of low quality if “further 
research is very likely to have an important impact on our confidence in the estimate 
of effect and is likely to change the estimate”, and very low quality if “we have very 
little confidence in the effect estimate”. We began the rating of the quality of evidence 
with the study design; evidence from systematic reviews of randomised controlled 
trials as high-quality and that from systematic reviews of observational studies as 
low-quality. In addition, five reasons led us to downgrade the quality of evidence from 
systematic reviews of randomised controlled trials and three to upgrade the quality of 
evidence from systematic reviews of observational studies. For pooled data from 
randomised controlled trials, the factors that led to rating down the quality of evidence 
were risk of bias, heterogeneity, indirectness, imprecision, and publication bias. 
Regarding risk of bias, concerns that limited our confidence in the evidence include 
lack of allocation concealment, lack of blinding of outcome assessment, and a large 
loss to follow-up. Heterogeneity of effects across studies for which there were no 
compelling explanations also reduced our confidence in the evidence. Indirectness 














outcome of interest to us, and those included in the relevant reviews. For imprecision, 
if we found that studies included relatively few participants and few events and thus 
had estimates of effects with wide confidence intervals, we rated down the quality of 
the evidence. Finally, we downgraded the quality of evidence if there was a high 
likelihood of publication bias.  
 
5.3.3. Search and selection of randomised controlled trials 
We complemented the search for systematic reviews with an exhaustive search for 
randomised controlled trials conducted in low and middle-income countries (Appendix 
3), which have not yet been the subject of any systematic review of strategies for 
improving immunisation coverage. Between 27 March 2012 and 30 June 2012 we 
searched the electronic databases indicated below, selected eligible trials, and 
assessed the risk of bias in selected trials using standard Cochrane criteria i.e. 
random sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, and selective 
outcome reporting, and other sources of issues.135 For each trial, we described what 
the trial authors reported that they did for each domain and made a decision relating 
to the risk of bias for that domain by assigning a judgement of 'low risk' of bias, 'high 
risk' of bias, or 'unclear risk' of bias.  The databases searched were the Cochrane 
Central register of Controlled Trials (CENTRAL), Cochrane Library, Issue 3, 2012; 
Medline In-Process and Ovid Medline, 1946 to present; Embase, 1980 to present; 
CINAHL (EBSCO), 1981 to present; LILACS (VHL); and Sociological Abstracts, 1952 

















The search for systematic reviews yielded 1369 records as shown in Appendix 2. 
Detailed screening of titles and abstracts yielded 16 potentially eligible reviews.54, 120-
124, 136-145 Following screening of the full-text publications we included 11 systematic 
reviews in this study.54, 120-124, 136-140 The five remaining systematic reviews were 
excluded either because a more recent or a more complete one on the same topic 
was included.141-145 The characteristics of the systematic reviews are shown in Table 
8.  
The search for randomised controlled trials identified 542 records in CENTRAL; 2179 
records in Medline; 879 records in Embase,; 66 records in Cinahl; 88 records in 
Lilacs; and 116 records in Sociological Abstracts. After removing duplicates, we were 
left with 3868 records. We then screened the titles and abstracts of the 3868 records 
and found 13 potentially eligible studies.146-158 We retrieved the full text of the 18 
articles, scrutinised them, and found five randomised controlled trials that met our 
eligibility criteria.146-150 
The first review evaluated the effectiveness of home visiting programmes on the 
uptake of childhood immunisation  (Table 8).136 The authors (Denise Kendrick and 
colleagues) included 11 studies published by July 1996. Nine of the 11 studies 
reported comparable immunisation coverage data and their results were pooled in a 
meta-analysis. Fixed effect meta-analysis gave a pooled odds ratio (OR) of 1.40, 
95% confidence intervals [CI] 1.16 to 1.68; with significant unexplained heterogeneity 
(heterogeneity P=0.005). The authors then conducted a random-effects meta-
analysis, which did not show home visiting programmes to be effective in increasing 














Table 8: Characteristics of included systematic reviews 
 Review ID*  
 









To assess the effects of 
home visiting programmes 
on the uptake of 
immunisation 
Medline, Cinahl, Embase, 
Cochrane Library, the 




Last search: Sep 1996 
Output: 1218 records 
Potentially eligible: 102 
articles 
Included: 11 studies 
 
9 RCTs and 3 non-
RCTs 11 of home 
visiting programmes 
with at least one 
postnatal visit 






study selection, critical 








To assess the effects of 
mass mailings on influenza 
immunisation coverage 
among Medicare 
beneficiaries in the USA 
 
Health Care Quality 
Improvement Project 
database for controlled trials 
completed since 1993 
 
Last search: 1999 
(month not specified) 
Output: 6 records 
Potentially eligible: 6  
Included: 6 studies 
5 RCTs and 1 CCT of 
letters and post cards  
USA (n=6)  Conducted duplicate 
study selection, critical 









To summarise the 
effectiveness of audit and 
feedback on immunisation 
delivery 
Medline, reference lists, 
authors’ personal files 
 
Last search: 1998 
(month not specified) 
Output: 60 records 
Potentially eligible: 44 
Include: 15 studies 
 
6 ITS, 5 RCTs, and 4 






study selection, critical 






4 Stone 2002.139 
 
To assess the relative 
effectiveness of previously 
studied approaches for 
improving adherence to 
adult immunisation and 
cancer screening guidelines 
 
Medline, EPOC register, 
Medicare Health Care 
Quality Improvement Project 
database, reference lists 
 
 
Last search:  Feb 1999. 
Output: 655 records. 
Potentially eligible: 137 
Included: 108 studies 
95 RCTs and 13 CCTs 
of reminder, feedback, 
education, financial 
incentive, organisational 
change, & mass media 
interventions 
Not reported (but 
studies likely to be 
mainly from USA) 
Conducted duplicate 
study selection, critical 












To assess the effectiveness 
of patient reminder and 
recall systems in improving 
immunisation rates 
Medline,  Embase, Cinahl, 
PsychINFO, Sociological 
Abstracts, CAB Abstracts,  
EPOC register, reference 
lists, scientific meetings, 
authors’ personal files 
Last search: May 2007 
Output: 398 records 
Potentially eligible: 122 
Included: 47 studies 




person phone calls, & 
outreach 
 
USA (n=36),  




(n=2), & UK (n=1)  
 
Conducted duplicate 
study selection, critical 






6 Pegurri 2005.122 
 
 
To describe the available 
literature about interventions 
designed to increase 
coverage; and to identify the 
interventions which can be 
reliably accepted as 
effective and cost-effective. 
 
Medline, Popline, BIDS, 
CAB Abstracts, Web of 
Science, PubMed, EconLit, 
HEED, Cochrane Library, 
WHO regional databases.  
Last search: Dec 2001. 
Output: 2621 records. 
Potentially eligible:  152 
Included: 60 studies 
3 RCTs and 57 




Asian / Pacific 
(n=6), and Central 
or South American 
(n=6) countries. 
Conducted duplicate 
study selection, critical 
appraisal, and data 
extraction; and meta-








7 Batt 2004.120 
 
 
To review the grey literature 
on the costs and effects of 
expanding immunisation 
services in low and middle-
income countries. 
WHO, UNICEF, PAHO, 
USAID, World Bank, 
UNICEF, BASICS II, PAHO, 
GAVI, DFID, National EPI 
programmes, SIGLE, Eldis, 
HTA Centre in York, 
Last search: May 2003 
Output: 1979 records. 
Potentially eligible:  88 
Included: 34 studies 
34 studies, none of 
them a controlled trial. 
 
African (n=11), 
Central and South 
American (n=7), 
and Asian/Pacific 
(n=6) countries.  
 
Conducted duplicate 
study selection, critical 
appraisal, and data 
extraction; and meta-



















 Review ID*  
 





Popline, CAB abstracts, 
regional WHO databases, 
Google, NGOs, consultancy 
firms, universities, BASICS 
II, PATH, Tearfund 
 
8 Ryman 2008.123 
 
 
To determine strategies that 
may be used at the sub-
national level to improve 
routine immunisation 
programmes 
Medline, Embase, Cinahl, 
Sociological Abstracts, 
CENTRAL, ERIC, CDSR, 
DARE ACP Journal Club, 
CCTR, Web of Science, 
CAB Direct, Anthropology 
Plus, Access UN, and many 
other databases and 
websites/online resources. 
 
Last search: 2005 
(month not specified) 
Output: 11,500 records 
Potentially eligible: 264 
Included: 25 studies 
 
9 RCTs, 10 CBAs, and 
6 observational studies 











study selection, critical 
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To evaluate the 
effectiveness of intervention 
strategies to boost and 
sustain high childhood 
immunization coverage in 
LMICs 
Medline, CENTRAL, 
Embase; Cinahl, EBSCO, 
LILACS, Sociological 
Abstracts, DARE, reference 
lists.  
 
Last search: March 2011  
Output: 3678 records 
Potentially eligible: 46 
Included: 6 studies 
6 RCTs of patient 
oriented, provider-
oriented, and health 
system interventions; 





and Central and 
South American 
(n=1) countries  
Conducted duplicate 
study selection, critical 
appraisal, and data 
extraction; and meta-
analysis and narrative 
synthesis. 
Moderate: 











To assess the effects of 
LHW interventions on the 
uptake of childhood 
immunisation and to develop 
a typology of intervention 
models. 
Medline, CENTRAL, 
Embase, Cinahl, British 
Nursing Index and Archive, 
AMED, POPLINE, WHOLIS, 
reference lists, contact 
experts/authors. 
 
Last search: Feb 2009 
Output: 3315 records. 
Potentially eligible: 55 
Included: 12 studies 
10 RCTs, 1 CBA, and 1 
ITS studies in which the 
LHWs either promoted 




USA (n=6), Ireland 








study selection, critical 








To assess the effectiveness 
of interventions proposed by  
EPI managers for improving 
programme performance 
PubMed, Health Systems 




Last search: Nov 2011 
Output: 2538 records 
Potentially eligible: 757 
Included: 10 SRs 
5 SRs of supply-side 
and 5 SRs of demand-
side interventions.  
 
Not reported, but 
studies included in 





study selection, critical 












* Surname of first author, year, and study reference; ** GRADE Quality of evidence categories are explained in the text; *** Only year of search given in the report, with no month 
specified.  
BASICS II, Basic Support for Institutionalizing Child Survival - stage II; CBA, controlled before-and-after study; CENTRAL, Cochrane Central Register of Controlled Trials; CHW, 
community health workers; DARE, Database of Abstracts of Reviews of Effectiveness; DFID, UK Department for International Development; EPOC, Cochrane Effective Practice and 
Organisation of Care Group; GAVI, The Global Alliance for Vaccines; HTA, Health Technology Assessment; ITS, interrupted time series analyses; LHW, lay health workers; LMICs, 
low and middle-income countries; NGOs, Non-governmental organisations; PATH, Program for Appropriate Technologies in Health; PAHO, Pan American Health Organization; RCT, 














We concluded that this review provided very low quality evidence that home visiting 
programmes could improve childhood immunisation coverage in Africa. Our main 
concerns were the unexplained heterogeneity in study results and the indirectness of 
the evidence; since there are marked differences in health systems between the 
Europe and North America (where the included studies were conducted) and African 
countries.159, 160   
We did not find recent randomised controlled trials that assessed the effects of home 
visits on childhood immunisation coverage in low and middle-income countries. 
However, unlike in western countries, home visits in most of Africa would be 
conducted by community health workers; to identify un-immunised children and refer 
them for immunisation at the nearest health centre. As discussed later in this chapter, 
three systematic reviews which focused on studies from low and middle-income 
countries provide moderate quality evidence that the use of community health 
workers improves childhood immunisation coverage in Africa.121-123 
The second review assessed the effects of mass mailings on influenza immunisation 
coverage among Medicare beneficiaries in the United States of America (USA) 
(Table 8).137 Under Medicare in the USA, each state and territory is affiliated with a 
Peer Review Organization, which is required to conduct quality improvement projects 
and file reports of their results as part of the Health Care Quality Improvement 
Project. In early 1999, Margaret Maglione and collaborators searched the Health 
Care Quality Improvement Project database for controlled trials completed since 
1993; the year coverage began for influenza vaccine. The authors identified six 
controlled trials of mass mailings. The first trial found a statistically significant, but 
modest improvement in influenza vaccination coverage among study participants 
who received a letter compared to those who did not, and was published in the 
Morbidity and Mortality Weekly Report. None of the five subsequent studies reported 
clinically meaningful results, and none of them was ever published. The mass 
mailings discussed in the review were not sent by the study participants’ personal 
clinics or physicians, and are thus conceptually different from recall and reminders by 














have had clinically trivial effects on increasing influenza vaccination among Medicare 
beneficiaries in the USA.137  
We conclude that this review provides very low quality evidence that mass mailings 
could improve childhood immunisation coverage in Africa. The factors that lowered 
our confidence in the effectiveness of mass mailing to improve childhood 
immunisation coverage in Africa were the heterogeneity of effects and the 
indirectness of the evidence; since the review included only studies conducted 
among the adult population receiving preventive care from Medicare in the USA. 
These data may thus be of limited relevance to childhood immunisation programmes 
in Africa.159 We found no new randomised controlled trial on mass mailing from a low 
or middle-income country. However, if mass mailing were found to be an effective 
strategy for improving immunisation coverage, it could easily be implemented in most 
African countries using mobile phone text messaging. 
The third systematic review assessed the effects of audit and feedback on 
immunisation delivery by healthcare workers.138 The review authors (Clayton Bordley 
and colleagues) defined audit and feedback as “any summary of clinical performance 
gathered over a defined period of time and presented to the healthcare provider after 
collection”. They included 15 studies in the review, conducted in the USA (n=13) and 
United Kingdom (n=2); five of them randomised controlled trials (Table 8). Twelve 
studies found that audit and feedback was associated with improvements in 
immunisation coverage. The magnitude of effect varied from -17% to +49% change, 
but study design heterogeneity precluded a meta-analysis. Five of the fifteen 
included studies involved interventions aimed at increasing childhood immunisation 
coverage. Of these five, one was a randomised controlled trial, two were interrupted 
time series analyses, and two were before-and-after studies. The increase in 
childhood immunisation coverage in the five studies ranged from +3% to +25% 
percentage points. 
Using the GRADE approach, we rated the quality of evidence from this review on the 
effectiveness of audit and feedback for improving childhood immunisation coverage 














evidence was indirectness (since the included studies were conducted in high-
income countries and may not be directly relevant to national health systems in 
Africa).  
We did not find a recent randomised controlled trial on the effects of audit and 
feedback for improving immunisation coverage in a low or middle-income country. 
However, a recent Cochrane review by Noah Ivers and colleagues provides high 
quality evidence that audit and feedback improves health worker behaviour.161 The 
authors found the weighted median adjusted risk difference from 49 high-quality 
studies to be +4.3% (interquartile range +0.5% to +16%) absolute increase in 
healthcare professionals' compliance with desired practice. They also found the 
effect of audit and feedback to be larger when baseline performance was low, the 
source was a supervisor or senior colleague, delivered both verbally and written, 
provided more than once, and included both explicit targets and an action plan. We 
are confident that the findings of the Cochrane may be applicable to childhood 
immunisation programmes in Africa. 
In the fourth included review, Erin Stone and colleagues assessed the effectiveness 
of interventions to increase the uptake of adult immunisation and cancer screening 
services.139 The authors identified 108 controlled trials published by February 1999, 
which assessed the effectiveness of interventions to increase the use of 
immunisations for influenza and pneumococcal pneumonia as well as screening for 
colon, breast, and cervical cancer in adults; 95 randomised controlled trials and 13 
non-randomised controlled trials (Table 8). Twenty nine studies focused on 
immunisation. Meta-regression revealed the adjusted odds ratios (OR) for increasing 
immunisation coverage to be 16.00 (95%CI 11.2 to 22.8) for organisational change; 
3.80 (3.31 to 4.37) for provider reminders; 3.42 (2.89 to 4.06) for patient financial 
incentives; 3.21 (2.24 to 4.61) for provider education; 2.52 (2.24 to 2.82) for patient 
reminders; 1.29 (1.14 to 1.45) for patient education; 1.26 (0.83 to 1.90) for provider 
financial incentives; and 1.23 (0.96 to 1.58) for feedback. The organisational change 
studies in the meta-regression analysis could be classified into four general 














prevention activities, use of a planned care visit for prevention, use of techniques 
similar to continuous quality improvement, and designation of specific prevention 
responsibilities to non-physician staff. Patient financial incentives included reducing 
or eliminating co-payments, which would not be applicable to childhood immunisation 
services in Africa that are provided at no cost to recipients in public health facilities. 
Client reminders consistently improved coverage, with personalised reminders or 
reminders signed by the patient’s physician being more effective than generic 
reminders. The authors went on to do an exploratory analysis of features 
instrumental to the success of each organisational change intervention, using meta-
regression. They found that explicitly designing an intervention that fosters 
collaboration or teamwork (OR 17.9, 95%CI 10.4 to 30.9), provides materials with 
high visual appeal (OR 3.25, 95%CI 2.09 to 5.06), or is based on needs or theory 
(OR 1.61, 95%CI 1.52 to 1.71), was associated with a statistically significant increase 
in immunisation coverage. In conclusion, this review suggests that the best strategies 
to increase immunisation coverage in an adult population in a high-income setting is 
implementation of organisational changes that  involve collaboration and teamwork 
and are based on knowledge of needs, barriers, and theory; followed by patient 
reminders and  patient financial incentives in that order.139  
The included studies were conducted in high-income countries among adult 
populations. These factors limit our confidence in the transferability of these findings 
to childhood immunisation programmes in Africa, and we rated the quality of 
evidence as moderate for organisational change and parent reminders. Parent 
reminders can play a big role in EPI programmes in Africa especially with the 
widespread use of mobile phones in the continent; and are covered by the next 
review.124  
We found a recent randomised controlled trial that assessed the effects of 
organisational change interventions on immunisation coverage in rural hard-to-reach 
populations in Bangladesh.150 In this trial, Jasim Uddin and colleagues chose two 
sub-districts with the lowest immunisation coverage from each of two hard-to-reach 














two interventions (modified EPI immunisation session schedule and community 
support groups), and one sub-district (Group B) was chosen to receive a different 
intervention (screening checklist). Modified EPI session schedules consisted of 
alternate session schedules intended to make EPI sessions more efficient, 
accessible, and convenient. In addition, community support groups (one for each EPI 
centre) were formed to involve the community with the EPI. The authors assessed 
the impact with post-intervention coverage surveys conducted in May 2010. The 
immunisation coverage increased significantly at endline compared to baseline in the 
study areas (p < 0.001). The findings also showed that the number of drop-outs and 
left-outs decreased significantly at endline compared to baseline in the study areas (p 
< 0.001). Drop-outs refer to children who start but do not complete the full series of 
vaccines on the schedule, while left-outs refer to children who have not yet taken any 
vaccines on the schedule. 
In the fifth included review, Jacobson Vann and co-worker assessed the 
effectiveness of patient reminder and recall systems in improving immunisation 
coverage and compared the effects of various types of reminders in different settings 
or patient populations.124  The authors found 47 trials published by 2007, twenty 
three of which are relevant to childhood immunisation. The rest involved influenza 
immunisations for patients 65 years or older, those with chronic illness, or both. 
Interventions included letters, postcards, person-to-person telephone calls, computer-
to-person telephone calls, and home visits. Most of the studies were done in the 
USA; with none done in low or middle-income countries. The included studies were, 
however, done in diverse settings, some of which were aimed at low-income groups 
in high-income countries. The authors found that increases in immunisation coverage 
due to reminders were in the range of 1 to 20 percentage points. Reminders and 
recalls were effective for routine childhood vaccinations (OR 1.47, 95% CI 1.28 to 
1.68) and childhood influenza vaccinations (OR 2.18, 95% CI 1.29 to 3.70). All types 
of reminders were effective, with the use of telephones being the most effective but 














We rated the quality of evidence on the use of parent reminder and recall systems for 
improving childhood immunisation coverage in Africa as moderate. Our main concern 
was indirectness of the evidence (because the review provided no direct evidence of 
how effective reminder and recall interventions are in low and middle-income 
countries). We did not find a recent randomised controlled trial on reminder and recall 
for improving childhood immunisation coverage in low and middle-income countries.  
The sixth systematic review, conducted by Elisabetha Pegurri and colleagues, 
assessed the range of potential effects and costs of interventions to expand the 
coverage of immunisation programmes in low and middle-income countries 
(Table8).122  The authors conducted a comprehensive search and identified 60 
papers which they included in the review. Three of the publications were reports of 
randomised controlled trials and the rest were ecological studies. The studies 
assessed 49 distinct interventions, with 44 evaluated for effectiveness, 10 for costs, 
and three for cost-effectiveness. The interventions were most frequently reported 
from Africa (10 countries), Asia and the Pacific (n=6), and Central or South America 
(n=6). The authors found that supply-side interventions such as improvements in 
healthcare worker performance (through training, monitoring, and supportive 
supervision), bringing services closer to the people (through outreach teams or 
community health workers), and modification of immunisation schedules (to target 
children when more are likely to visit health centres by delivering the vaccines earlier 
and/or at shorter intervals) were effective in increasing immunisation coverage. 
Increasing demand among those already accessing health services was attempted 
by reorganising clinic procedures so as to shorten waiting times and by reducing 
missed opportunities (e.g. vaccinating all eligible children visiting health centres, even 
if ill). Reminders were used to target children that had accessed services in the past 
but had not returned. Children’s records were sorted according to the time the next 
vaccination was expected in order to identify non-attendees and send reminders to 
their families, sometimes through school children. Channelling (or door-to-door 
canvassing) was also used in some studies to encourage non-returnees as well as 
those who have never attended vaccination clinics. Community health workers 














and referred them to health centres. Different strategies were used in various studies 
for increasing awareness among the children’s parents including mass media 
interventions and provision of immunisation information to older children in schools. 
The authors found that all interventions increased vaccination coverage, with 
community health workers and channelling being the most effective and peer training 
and channelling the least costly.  
We rated the quality of evidence as moderate for community health workers and 
channelling, and low to very low for the rest of the interventions. The main factors 
that reduced our confidence in the evidence are study limitations i.e. the low quality 
of the studies included in the review.122  
The seventh included review was a review of the grey literature on the costs and 
effects of expanding immunisation services in low and middle-income countries, by 
Katherine Batt and colleagues.120  The authors hand-searched documents at the 
headquarters of the WHO, UNICEF, Pan American Health Organization (PAHO), and 
USAID; and interviewed 28 international experts from The World Bank, UNICEF, 
Basic Support for Institutionalizing Child Survival – stage II (BASICS II), The United 
States National Institutes of Health, PAHO, WHO country offices, and national EPI 
programmes. In addition, they searched a wide range of grey literature databases 
(Table 8). The authors identified 34 relevant publications (of 24 interventions), which 
were available by May 2003. The interventions were evaluated in Africa (n=11 
countries), Central and South America (n=7), and Asia and the Pacific (n=6). Supply-
side interventions focused on endowing providers with increased responsibility and 
accountability by changing payments to performance-based systems and contracting 
with non-governmental organisations at varying levels of responsibility to provide 
immunisation services. Demand-side strategies were aimed at educating 
communities and health workers, improving awareness of missed opportunities, and 
reducing opportunity costs to families (e.g. by shortening waiting times).  
This grey literature review provides low quality evidence that mass media, education 
for health workers, in-service training, community education, contracting out, 














integrated supervisory checklists could improve childhood immunisation coverage in 
Africa. Although all studies were conducted in low and middle-income countries, our 
confidence in the effectiveness of these interventions for improving childhood 
immunisation programmes in Africa was reduced by the paucity of randomised 
controlled studies.122 
In the eighth included review, Tove Ryman and colleagues conducted a 
comprehensive search of peer-reviewed and grey literature on strategies for 
improving childhood immunisation in low and middle-income countries.123 They 
identified 25 papers that met their inclusion criteria i.e. a fairly rigorous study (not 
necessarily a controlled trial) conducted to improve routine immunisation 
programmes among humans in a low- or middle-income country. The authors 
grouped the papers into four strategic approaches: bringing immunisations closer to 
communities (n=11), using information dissemination to increase demand for 
vaccination (n=3), changing practices in fixed sites (n=4), and using innovative 
management practices (n=7).   
The studies included in the category “bringing immunisations closer to communities” 
used community health workers to encourage people to seek immunisation services, 
or increased access to immunisation services by bringing services to communities, 
and additionally in some cases by increasing demand through educating 
communities. These studies were conducted in Africa (n=6), Asia and the Pacific 
(n=3), and Central and South America (n=1); and reported improvements in 
immunisation coverage of varying degrees. All six controlled clinical trials that 
reported data on fully vaccinated children recorded improvements in coverage 
ranging from 14% to 42%.  
Three studies (one before-and-after and two observational) were conducted in Asia 
to assess the “use of information dissemination to increase demand for vaccination”. 
Information can be provided through numerous channels to either increase 
awareness of the benefits of immunisation or to promote participation. These 
strategies increase demand for vaccination without changing the service delivery. 














people, if access to the type of media selected is good. The controlled before-and-
after study evaluated a mass media campaign focusing on measles vaccination 
delivered through routine services. An increase of 11% in the proportion of fully 
vaccinated children was observed with a year of starting the study. The two 
observational studies also led to increases in vaccination coverage.  
Four studies assessed the effects of “changing fixed vaccination sites” to ensure that 
children who start vaccination complete the full series of vaccines (i.e. reducing drop-
outs) and that children eligible for vaccination who come to the health facility are 
vaccinated (i.e. reducing missed opportunities). In a controlled trial in Ethiopia, the 
use of reminder stickers for parents resulted in decreasing dropout between the first 
and the third dose of the diphtheria-tetanus-pertussis vaccine from 13% to 7%. An 
observational study conducted in Sudan increased vaccination coverage by 32% by 
moving the immunisation location closer to the consultation room to provide 
immediate immunisations to children who had recently been seen in consultation, or 
having a physician write a prescription for immunisations during curative visits. A 
controlled before-and-after study in an urban setting in Nigeria increased the 
proportion of fully vaccinated children by 18% through reducing wait times by creating 
a quick immunisation line. In an observational study in a Mexican children's hospital 
missed opportunities were reduced by immunising all hospitalised children who were 
not up-to-date with their vaccines.  
Two controlled before-and-after studies and four controlled trials in Asia and the 
Pacific (n=3), Central and South America (n=2) and Africa (n=1) assessed the effects 
of “using innovative management practices” (i.e. who should manage immunisation 
systems, and how systems might be improved to provide the highest quality services) 
on immunisation coverage and equity. These interventions (including contracting 
immunisation services to NGOs, use of data and community information for planning 
immunisation activities, peer-support) significantly improved immunisation coverage.   
We rated the quality of evidence as moderate for strategies for bringing 
immunisations closer to communities (e.g. the use of community health workers) and 














of the interventions assessed by Tove Ryman and co-workers.123 The main concern 
with the evidence is the paucity of scientifically rigorous studies.   
Through an exhaustive search, we have identified new high-quality studies 
conducted in low and middle-income countries on interventions for improving 
childhood immunisation coverage.146-150 We have reported the findings of these 
studies elsewhere in this chapter. 
In the ninth included review, Oyo-Ita and colleagues assessed the effectiveness of 
strategies to boost and sustain high childhood immunisation coverage in low and 
middle-income countries.121 The authors conducted a comprehensive search for 
randomised controlled trials, non-randomised controlled trials, and interrupted-time-
series studies which were published by March 2011. They identified six studies; all of 
them randomised controlled trials. The studies were carried out in Asia and the 
Pacific (n=3), Europe (n=1), Central and South America (n=1), and Africa (n=1). The 
review provided low quality evidence that facility-based health education may 
improve immunisation coverage (RR 1.18, 95% CI 1.05 to 1.33), and that a 
combination of facility-based health education and redesigned immunisation cards 
may improve coverage (RR 1.36; 95% CI 1.22 to 1.51). They also found moderate 
quality evidence that evidence-based discussions during home visits improve 
immunisation coverage (RR 2.17, 95% CI 1.80 to 2.61). Our main concerns with the 
evidence from this review relates to study limitations; with four studies having a high 
risk of bias.  
Our search identified a new randomised controlled trial by Hussain Usman and 
colleagues,149 which assessed the effects a combination of facility-based health 
education and redesigned immunisation cards in a rural community in Pakistan.  The 
study authors state that the EPI card currently used in Pakistan has two main 
shortcomings i.e. it is small (hence, information on child’s identity, immunisation 
schedule, information for mothers and next immunisation visits is crowded), and  
immunisation appointment dates are hand-written, often in very small and irregular 
letters). To address these issues, the authors designed a new simpler immunisation 














mothers of the next immunisation visit and to make it easy for them to locate and 
read the date of the next immunisation. Mother-child pairs were enrolled when they 
came for the first dose of the diphtheria-tetanus-pertussis vaccine and randomised to 
four study groups: redesigned card (n=378), facility-based education (n=376), 
combined redesigned card and facility-based education (n=374), and standard care 
(378). Children in the redesigned card (RR 1.7, 95% CI 1.5 to 2.0), facility-based 
education (RR 1.5, 95% CI 1.3 to 1.8) and combined intervention group (RR1.7, 95% 
CI 1.4 to 2.0) groups were significantly more likely to complete the full three series of 
the diphtheria-tetanus-pertussis vaccine than those in the routine care group. This 
trial strengthens the evidence that facility-based education to mothers and a 
combination of facility-based education and user-friendly immunisation cards 
probably improve childhood immunisation coverage in Africa. 
In the tenth included review, Claire Glenton and colleagues assessed the effects of 
community health worker interventions on childhood immunisation coverage.140 They 
conducted the last search in 2009 and identified twelve studies, ten of which were 
randomised controlled trials. Five of the studies were carried out in low and middle-
income countries in Asia and the Pacific (n=2), Africa (n=1), Europe (n=1), and 
Central and South America (n=1). The studies from low and middle-income countries 
were conducted among poor populations or populations from areas where 
immunisation coverage was particularly low; in both urban and rural settings. The 
studies from high-income countries took place among economically disadvantaged 
urban populations. In ten studies, community health workers promoted childhood 
immunisation and in the remaining two studies, community health workers vaccinated 
children themselves. In most of the studies, the control group populations received 
standard care or no intervention. Most of the studies showed that community health 
workers increased immunisation coverage.  
We rated the quality evidence on the effectiveness of community health workers to 
increase childhood immunisation coverage as moderate.  Our concern with the 
evidence is the paucity of high-quality studies from low and middle-income countries 














In the eleventh included review, Charles Wiysonge and colleagues requested EPI 
programme managers in South Africa to identify key barriers to effective 
implementation of the EPI programme and to propose appropriate corrective 
interventions.54 The authors collated the managers’ responses and conducted a 
comprehensive search for systematic reviews on the effectiveness of the proposed 
corrective interventions.  The authors conducted the last search in November 2010 
and identified 10 systematic reviews that met their inclusion criteria. The latter were 
reviews which: (1) conducted a literature search that was comprehensive enough to 
avoid publication, language and indexing biases; (2) undertook duplicate study 
selection and data extraction; (3) used reliable criteria to assess the risk of bias in 
included studies;  (4) reported the characteristics of included studies appropriately; 
and (5) combined data from included studies using reliable methods. The authors 
found high-quality evidence that interactive educational meetings, audit and 
feedback, and supportive supervision of healthcare workers are effective supply-side 
interventions for improving childhood immunisation coverage. Regarding demand-
side interventions, the authors found moderate quality evidence that parent reminder 
and recall systems, use of community health workers, mass media interventions, 
conditional cash transfers, and structured interactive communication lead to 
improvements in childhood immunisation coverage. Conditional cash transfers refer 
to monetary transfers made to disadvantaged households on the condition that they 
comply with some pre-determined requirements in relation to health care, such as 
vaccinating their children.162 
We found newly published randomised controlled trials which increased our 
confidence in the effectiveness of consumer incentives and community health 
workers for improving immunisation coverage,146, 148 and in the integration of 
immunisation services to other primary health care services.147 
Abhijit Banerjee and colleagues used a clustered randomised controlled study design 
to assess the efficacy of modest non-financial incentives on immunisation coverage, 
compared to the effect of only improving the reliability of the supply of services.146 














immunisation clinic (intervention A; 379 children from 30 villages); a once-monthly 
reliable immunisation clinic with small incentives (raw lentils and metal plates for 
completed immunisation; intervention B; 382 children from 30 villages); or control (no 
intervention, 860 children in 74 villages); in Rural Rajasthan, India, from June 2004 to 
February 2007. Among children aged 1-3 in the end point survey, rates of full 
immunisation were 39% (148/382) for intervention B villages (reliable immunisation 
with incentives), 18% (68/379) for intervention A villages (reliable immunisation 
without incentives), and 6% (50/860) for control villages. After 18 months, the risk 
ratio for complete immunisation was 6.7 (95%CI 4.5 to 8.8) for reliable immunisation 
with incentives compared to no intervention, and 2.2 (1.5 to 2.8) for reliable 
immunisation with incentives compared to reliable immunisation without incentives. 
The average cost per immunisation was 28.00USD for reliable immunisation without 
incentives and 56.00USD for reliable immunisation with incentives.  
In another trial, Aatekah Owais and colleagues conducted a randomised controlled 
trial to assess the impact of a low-literacy immunisation promotion educational 
intervention for mothers living in low-income communities in Pakistan on completion 
of the immunisation schedule.148 Three hundred and sixty-six mother-infant pairs, 
with infants aged six weeks or less, were enrolled and randomised into either the 
intervention or control arm between August and November 2008. To address the 
needs of low literacy populations, easy-to-understand pictorial cards, using very 
simple language, to convey three key messages as part of the educational 
intervention were designed. The first key message highlighted how vaccines save 
children’s lives. The second message provided logistic information about the address 
and location of the local vaccination centres. The third key message emphasised the 
significance of retaining immunisation cards, and the role they could play at the time 
of the child’s school admissions. A copy of these pictorial messages was left with the 
mother. The intervention was delivered by trained community health workers during 
home visits, and it lasted about five minutes. The control group received general 
health promotion messages (hand-washing, breast-feeding, clean water, benefits of 
using oral rehydration solutions during diarrhoea, bringing the infant to nearby health 














antenatal check-ups for mothers, and general information on vaccines) verbally. The 
control group intervention was delivered by trained community health workers and 
lasted approximately 10-15 minutes. At the four month assessment, among 179 
mother-infant pairs in the intervention group, 129 (72.1%) had received DTP3, 
compared to 92/178 (51.7%) in the control group. Multivariable analysis revealed a 
significant and clinically important increase of 39% (adjusted RR 1.39; 95% CI 1.06 
to1.81) in DTP3 coverage in the intervention group. The cost of the intervention per 
community health worker was estimated to be one USD; including the cost of 
laminated coloured pictorial cards used by the community health workers to educate 
the mothers in the intervention group, as well as pamphlets of the pictorial messages 
left at each participant’s house.148 
 In another recent study, an open cluster-randomised trial, Alassane Dicko and 
colleagues assessed the efficacy of Intermittent Preventive Treatment in infants 
(IPTi) with Sulfadoxine-Pyrimethamine (SP) implementation on the coverage of EPI 
vaccines; in Kolokani district in Mali.147 . The 22 sub-districts were randomised in a 
1:1 ratio with 11 intervention and 11 control sub-districts. The study began in 
December 2006 and ended in December 2007In December 2006, the proportion of 
completely vaccinated children aged 9-23 months was 37% (95% CI 25% to  48%). A 
year later, the figure had risen to 53.8% in the non-intervention zone and 69.5% in 
the intervention zone (P <0.001).  
 
5.5. Implication of the findings of Chapter Five 
African governments have the responsibility to provide basic services, including 
immunisation services, to their citizens. However, the public sector is not often 
sufficiently well-equipped and financed to provide high quality health services that are 
accessible to all in African countries. Therefore, health policymakers in Africa need to 
use considerable judgement about how best to use the limited resources they have 
allocated for improving childhood immunisation programmes in order to maximise 














that the use of interactive educational meetings and workshops, audit and feedback, 
supportive supervision, organisational changes (that involve collaboration and team 
work and are based on knowledge of needs, barriers, and theory), community health 
workers, (evidence-based discussions during) home visits, parent reminder and recall 
systems, targeted financial (and non-financial) incentives, mass media interventions, 
and interactive communication tools could be effective in improving EPI performance 
in Africa.  
The settings and designs of the studies included in the systematic reviews that 
assessed the effects of supply-side interventions such as interactive educational 
meetings, audit and feedback, educational outreach visits, and organisational 
changes varied widely; but the studies consistently showed that these strategies can 
improve healthcare worker performance.54, 139, 163-165 The consistency of effects 
across different study designs and healthcare settings and conditions suggests that 
these findings would be applicable to childhood immunisation programmes in Africa.  
Social mobilisation for immunisation may include active community participation, 
contextualisation of information and involvement of a broad range of stakeholders 
and the mass media. The moderate quality of the evidence on parent reminder and 
recall systems,124, 139 community health workers,122, 123, 140, 141 interactive 
communication tools, targeted consumer-directed incentives139, 146, 162, and mass 
media interventions122, 123, 125  is an indication that these strategies could have 
significant effects in mobilising communities and increasing demand for routine 
childhood immunisation services in Africa.  
Reminder and recall interventions rely crucially on a stable health system with 
ongoing immunisation programmes that can identify and follow potential recipients of 
vaccination. Other factors that need to be considered to assess whether the 
intervention effects are likely to be transferable to other settings include the 
availability of the technology or physical infrastructure to provide reminders (e.g. 
telephones, computers, a functioning postal system) and literacy of parents (e.g. for 
post cards); resources to provide the additional clinical and administrative 














of vaccines in health facilities. Low literacy levels may mean that the uptake of 
immunisations is not simply a matter of reminding parents.77 EPI programmes may 
need to provide educational interventions to explain the benefits of immunisation.148 
Although the issues we have raised above regarding the structural differences 
between countries where most of the reminder and recall studies were conducted 
and African countries are real issues, it is reassuring to note that other technologies 
and avenues exist for adapting reminders to the African context. Children’s 
immunisation records in health facilities should be sorted according to the time the 
next vaccination is due, and their parents contacted through school children, 
community health workers, or mobile phone text messaging to remind them of 
upcoming immunisations or ones that are overdue.158, 166, 167 
Growing financial pressure to improve the efficiency of health systems amidst a 
chronic shortage of qualified health workers in the public health sector, is also leading 
to an increased interest in broadening the scope of practice of community health 
workers in Africa.168 Vaccination of children by community health workers is highly 
relevant to such discussions. Four reviews included in our overview show promising 
benefits of community health workers on child immunisation coverage.121-123, 140 They 
identified a number of intervention models for community health workers. However, 
these models are not exhaustive and more high-quality studies are needed, 
particularly from Africa; for example, we have little knowledge about the effect of 
using community health workers as part of a larger team as only two studies used 
this approach.140 In addition, the costs and cost-effectiveness of using community 
health workers in immunisation programmes has not been fully evaluated. 140, 169 
A substantial proportion of the population in African countries seeks curative services 
in the private sector.72, 73, 170 However, relatively few data are available on the role of 
the private sector in the provision of immunisation services in the continent. 72 Ann 
Levin and co-worker suggest that the private sector plays different roles and 
functions in different countries, according to economic development levels and the 
governance structure.72 In low-income countries, the private for-profit sector 














vaccines.72, 74 In middle-income countries, the private for-profit sector often acts to 
facilitate early adoption of new vaccines and vaccination technologies before their 
introduction in the public health sector.72 The not-for-profit health sector plays an 
important role in extending access to traditional EPI vaccines, especially in low-
income countries. Not-for-profit facilities are more likely to be coordinated with public 
services than the private for-profit sector. Although numerous studies NGO’s suggest 
that the extent of NGO provision of immunisation services in low- and middle-income 
countries is substantial, the contribution of this sector is poorly documented. Studies 
on quality of immunisation service provision at private health facilities suggest that it 
is sometimes inadequate and needs to be monitored. Although some articles on 
public–private collaboration exist, the authors found little on the extent to which 
governments are effectively interacting with and regulating the private sector. They 
revealed many geographical and thematic gaps in the literature on the role and 
regulation of the private sector in the delivery of immunisation services in low and 
middle-income countries.72, 73 If Africa is to achieve its immunisation goals, public-
private partnerships need to be fully utilised to the best advantage in childhood 
immunisation programmes. Models for subcontracting immunisation services to the 
private sector should be tried, evaluated, and considered for scale-up if successful.170 
The strength of this chapter lies in our adherence to standard guidelines on the 
conduct and reporting of systematic reviews as well as grading of the quality of 
evidence. We conducted comprehensive searches, assessed study eligibility using 
pre-defined inclusion criteria, and extracted data in duplicate; resolving differences by 
consensus. The major weakness of the chapter relates to inherent shortcomings in 
the primary data of the included reviews. Most of the studies included in the reviews 
were conducted in high-income countries, especially North America. However, we 
used novel methods to assess the quality of the evidence and its applicability to 















CHAPTER 6: Overall discussion and conclusion 
 
The following are novel contributions of this thesis to the field of vaccinology:  
1. Applying methods of evidence-based practice to childhood immunisation 
programmes in Africa; 
2. Conducting the first bibliometric analysis of childhood immunisation research 
productivity from Africa; 
3. Using advanced statistical techniques to determine the cross-continental 
factors that influence childhood immunisation coverage and research 
productivity in Africa; and 
4. Employing novel techniques such as GRADE in assessing the applicability of 
global evidence to the African immunisation context. 
This thesis employed evidence-based practice (EBP) techniques34, 35 to evaluate the 
performance of EPI in Africa, the reasons for poor EPI performance in Africa, and the 
current best evidence on effective interventions for improving the performance of EPI 
on the continent; focusing on immunisation coverage. The proportion of the annual 
birth cohort which receives the full series of three doses of the diphtheria-tetanus-
pertussis combined vaccine (DTP3) is an internationally accepted standard measure 
of immunisation coverage; and is generally accepted to reflect the overall 
performance of EPI programmes.8, 40, 41 EBP applies systematic and transparent 
processes when accessing and appraising research evidence, in order to ensure that 
decision making is well-informed by the best available research evidence.35 The EBP 
techniques employed in this thesis include systematic reviews (Chapter 2 and 5), the 
GRADE approach for assessing how much confidence to place in a given body of 
research evidence (chapter 5),134, 159 and an assessment of the applicability of global 
evidence to an African context (Chapter 5).160 In addition, we used generalised linear 
statistical models to assess factors associated with childhood immunisation coverage 














The first sub-study of the thesis was a systematic review, which found significant 
improvements in EPI performance in Africa since the inception of the programme in 
1974 (Chapter 2). A range of under-utilised vaccines, newly available vaccines, and 
new vaccination technologies are increasingly being introduced into national EPI 
programmes across the African continent.24, 26 Furthermore, basic immunisation 
coverage has increased significantly. Continental DTP3 coverage increased from 
less than 5% in 1974 to 77% in 2010.24, 33 However, the performance of EPI 
programmes varies widely between and within African countries, 24, 33, 47-49, 50 with 
many countries failing to meet the Global Immunisation Vision and Strategy (GIVS) 
targets.28, 29 In 2010, only 22(42%) countries achieved national DTP3 coverage of 
90% or more and only 16 (30%) achieved 80% DTP3 coverage in a least 80% of their 
districts. Besides, the quality of immunisation data in many African countries is poor, 
47-49 and vaccines are administered well after the recommended ages; leaving 
children exposed to deadly vaccine-preventable diseases for long periods. 50   
This continued failure to meet agreed targets suggests that general and country-
specific challenges with regards to immunisation programmes in Africa have not been 
fully identified, understood, and/or addressed effectively.77 With the 2015 deadline for 
the MDGs fast approaching, it is necessary for Africa to stop, critically assess its 
position, take ownership of the regional and country specific problems, and strategise 
exactly how it plans to overcome the challenges identified. The progress in 
immunisation coverage in most African countries (between 1980 and 1990, and since 
2000) has largely been due to the availability of international funding supplemented 
by government funding. Even with continued support from international donors, 
political will as well as financial planning and commitment from African governments 
are key factors for successful introduction and sustainability of new vaccines in EPI 
schedules on the continent. Regarding political commitment, The Republic of South 
Africa is to be commended for introducing several new vaccines in 2009 (i.e. the 
pneumococcal conjugate, rotavirus, and pentavalent vaccines) without external donor 
funding.54, 171 Vaccine procurement and pricing strategies, as well as vaccine 
adaptation to suit low and middle-income countries remain essential components of 














for Africa to take advantage of the new decade of vaccines and extend the full 
benefits of immunisation to its citizens by 2020 and beyond, a critical assessment is a 
fundamental step. The DoV recently coordinated the development of the Global 
Vaccine Action Plan (GVAP) which is guided by six principles; country ownership, 
shared responsibility and partnership, equity, integration, sustainability, and 
innovation.32 While such global initiatives offer generalised strategies for attaining 
outlined goals, it is absolutely necessary for complementary tailor-made African 
approaches. Evidence-informed African initiatives to improve immunisation coverage, 
strengthen immunisation systems, and hold African leaders accountable for 
honouring commitments made are urgently needed.  
In the second sub-study, we conducted the first ever bibliometric analysis of 
childhood immunisation research productivity from Africa (Chapter 3). We used 
negative binomial regression models to explore the factors associated with research 
output on the continent. Between 1974 and 2010 authors from Africa produced only 
8.9% of the global immunisation research output. Immunisation research productivity 
on the continent is highly skewed, with private health expenditure (which may reflect 
the economic development of a country) being the only independent predictor of 
research output. There was no significant association between research productivity 
and the country’s immunisation coverage or other country-level factors. The lack of 
association between research productivity and immunisation coverage may be an 
indication of a lack of interactive communication between health decision-makers, 
programme managers, and researchers. 
We recommended that during the new decade of vaccines, African countries should 
prioritise research capacity development in vaccinology in particular and in infectious 
diseases in general. Health research in general helps to answer questions, to 
generate the evidence required to guide policy, and to identify new tools. Therefore, 
contextualised research is needed to ensure the effectiveness, efficiency, and equity 
of immunisation policies in Africa. An evidence-informed approach to improving 
childhood immunisation programmes in Africa and, consequently, reducing child 














failed to reach their optimum potential. And secondly, appropriate strategies should 
be employed to address the identified shortcomings of immunisation programmes. 36-
39  
This was the rationale for the third sub-study, in which we developed and tested a 
model of childhood immunisation coverage that includes individual, community, and 
country level factors (Chapter 4).  We used multilevel logistic regression models to 
analyse Demographic and Health Survey data for 27,094 children aged 12 to 23 
months, nested within 8,546 communities from 24 countries in Africa. The model 
provides evidence of contextual factors, measured at community and country levels, 
associated with childhood immunisation coverage. At individual level, children from 
poorest households, uneducated parents, mothers with no access to media, and 
mothers with low health seeking behaviours were more likely to be unimmunised. In 
addition, we found evidence of clustering at both community and country levels, such 
that children from the same communities tended to have similar immunisation status. 
This suggests that children in the same neighbourhood are subjected to common 
contextual influences; thus, providing evidence of contextual phenomenon shaping 
children’s risk of being unimmunised. Furthermore, the analysis reveals that low 
parental and community knowledge of immunisation and/or lack of access to 
information on childhood immunisation could be an important contributor to the high 
burden of unimmunised children in Africa. This assertion is supported by our finding 
of significant reductions in the number of unimmunised children among parents and 
communities with access to mass media. In addition, unimmunised children were 
found to cluster in communities, increasing the risk of disease outbreaks. It is 
therefore important to identify effective interventions to enable parents and 
communities to understand the meaning and relevance of vaccination to their health 
and the health of their families and communities. The finding that individual and 
contextual factors are associated with childhood immunisation, suggests that public 
health programmes designed to improve childhood immunisation programmes in 
Africa should address people and the communities and societies in which they live. 














interventions to address these barriers should be a systematic and integral 
component of childhood immunisation programmes in Africa, and elsewhere.  
In the last sub-study, we conducted a comprehensive search of the peer-reviewed 
literature, identified, and synthesised randomised controlled trials and systematic 
reviews of effective interventions for improving childhood immunisation programmes 
(Chapter 5). Health policymakers in Africa need to use considerable judgement about 
how best to use the limited resources they have allocated for improving childhood 
immunisation programmes in order to maximise population benefits.  
This thesis has revealed moderate to high quality evidence that the use of interactive 
educational meetings and workshops, audit and feedback, supportive supervision, 
organisational changes (that involve collaboration and team work and are based on 
knowledge of needs, barriers, and theory), community health workers, (evidence-
based discussions during) home visits, parent reminder and recall systems, targeted 
financial (and non-financial) incentives, mass media interventions, and interactive 
communication tools could be effective in improving EPI performance in Africa. 
Decision makers need to consider population characteristics, available resources, 
and competing priorities when selecting a combination of these interventions to use 
for each community and at any given time point.  
A successful immunisation programme depends upon effective vaccine supply and 
logistics, but it is just as important that the community has confidence in, and 
supports and demands, safe and effective immunisation services.173 The moderate 
quality of the evidence on parent reminder and recall systems,124, 139 community 
health workers,122, 123, 140, 141 interactive communication tools,126 targeted consumer-
directed incentives139, 146, 162, and mass media interventions122, 123, 125  is an indication 
that these strategies could have significant effects in mobilising communities and 
increasing demand for routine childhood immunisation services in Africa. 
Immunisation services must meet the needs of communities and work with them to 
ensure their involvement and participation. To achieve this, both EPI managers and 
healthcare workers need to form a close partnership with communities, and use 














communities informed about services, and should seek the participation of local 
politicians, religious leaders, community group leaders, and parents in scheduling the 
days and hours for immunisation sessions, organising outreach activities, promoting 
immunisation, and monitoring performance. Advocacy is needed to promote the 
benefits and value of immunisation and to present the rationale for the community’s 
involvement. It is particularly important to increase immunisation demand at 
community level in countries with large numbers of un-immunised children. Wireless 
telecommunications networks have spread rapidly throughout Africa, and sending 
text-messages on wireless mobile telephones has become an extremely popular 
means of communication among people in all sectors of society. Therefore mobile 
phone text-messaging offer an appropriate channel for reminding parents of 
upcoming immunisations or immunisations that are overdue. 158, 166, 167  
Most of the evidence on the effectiveness of interventions for improving immunisation 
coverage comes from studies conducted in high-income countries, and applicability 
to African countries may be limited. Thus, the implementation of these interventions 
in childhood immunisation programmes in Africa should be pilot-tested and their 
impacts and costs rigorously monitored and evaluated.37 The range of interventions 
that we identified certainly does not exhaust the possibilities for increasing 
immunisation coverage. We propose the following areas for additional research, 
namely, use of school-based vaccination,174 innovative strategies for integration of 
additional services with immunisation delivery, public sector collaboration with and 
regulation of the private sector, best approaches to new vaccine introduction, and 
innovative ways of handling vaccine hesitancy and building or maintaining public trust 
in immunisation programmes.173 Accordingly, we suggest that more studies should 
be conducted in African countries. Such studies should be rigorously designed and 
executed; with long follow-ups, consideration of confounding factors, analyses of 
costs alongside effectiveness, and inclusion of broader outcomes regarding the 
quality and timeliness of vaccine delivery. These changes would improve the quality 
of study results, and African decision-makers could be more fully informed about the 
most desirable intervention or combination of interventions to improve immunisation 














African countries seeks curative services in the private sector.72, 73, 170 However, 
relatively few data are available on the role of the private sector in the provision of 
immunisation services on the continent. 72 If Africa is to achieve its immunisation 
goals, public-private partnerships need to be fully utilised to the best advantage in 
childhood immunisation programmes. Models for subcontracting immunisation 
services to the private sector should be evaluated, and considered for scale-up if 
successful.170 
In summary, this thesis has highlighted the importance of applying an EBP approach 
to immunisation policies in Africa. EBP is indispensable in health sciences; it helps to 
ensure that patients and the public benefit from health research, and that research 
and healthcare resources are used efficiently.175  Applying EBP principles to EPI in 
Africa will ensure that our children’s right to health, development and survival is 
respected, protected and promoted; in line with the Millennium Development Goals. 
The EBP approach emphasises the need for collaboration among health policy 
makers, programme managers, and researchers in order to ensure the effectiveness, 
efficiency, and equity of immunisation policies in Africa.54 This collaboration needs to 
be continuous, as challenges to childhood immunisation may vary from time to time; 
and policies would need to be adapted to the changing immunisation landscape. 
Such an approach would develop a comprehensive and relevant evidence base to 
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Appendix 1: Comparisons of Poisson and negative binomial regression models 
for the bibliometric analysis (Chapter 3)  
 
 
Test 1: The probability distributions which underpin the two models were 
examined to see how they fit the observed data 
 
 
Result: As shown in Figure 1, the Poisson model was a poor fit, whereas the 
predicted values of the negative binomial were close to the observed. The negative 
binomial model produced the best fit for the entire range of publication values 
 
 
Figure 1: Predicted proportions from intercept-only Poisson and negative 
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Test 2: Likelihood ratio test was used to test for overdispersion in Poisson 
regression model 
 
Result: As shown below, the likelihood test for overdispersion comparing 
negative binomial to Poisson, which test Ho, alpha=0, yielded statistics of 
764.72. The estimate of alpha was 0.85 (SE =0.18), which is significantly 




Poisson regression                      Number of obs   =         41 
                                        LR chi2(5)      =    1334.48 
                                        Prob > chi2     =     0.0000 








     log_gdp |   1.369986   .0681946     6.32   0.000      1.24264    
1.510382 
     log_phy |   .8296561   .0235366    -6.58   0.000     .7847843    
.8770937 
  log_heaexp |   .8495908    .113514    -1.22   0.222     .6538538    
1.103924 
 log_heapriv |   1.954061    .138539     9.45   0.000     1.700551    
2.245363 
    log_rand |   1.370433   .0637301     6.78   0.000     1.251048    
1.501211 







Negative binomial regression            Number of obs   =         41 
                                        LR chi2(5)      =      26.21 
Dispersion     = mean                   Prob > chi2     =     0.0001 




         pub |        IRR   Std. Err.      z    P>|z|  [95% Conf. Interval] 
-------------+-------------------------------------------------------------
--- 
     log_gdp |   1.408463   .3888345     1.24   0.215     .8198875    
2.419562 
     log_phy |    .812031   .1090316    -1.55   0.121     .6241393    
1.056486 
  log_heaexp |    .637382   .4984073    -0.58   0.565     .1376557    
2.951247 















    log_rand |   1.032388   .3032249     0.11   0.914     .5805431    
1.835909 



























Test 3: Bayesian Information Criterion (BIC), based on log likelihood was used 
as a measure of how well our different models fitted the data. A lower value on 
BIC indicates a better fit of the model 
 
 
Result: As shown below, BIC was significant to reveal that the negative 
binomial regression provided a good fit to the data than Poisson model, as 
indicated by lower BIC.  
 
Tests and Fit Statistics 
 
                               Current             Saved        Difference 
Model:                           nbreg           poisson 
N:                                  41                41                 0 
Log-Lik Intercept Only        -186.209         -1222.706          1036.497 
Log-Lik Full Model            -173.104          -555.464           382.360 
LR                              26.210(5)       1334.485(5)       
1308.274(0) 
Prob > LR                        0.000             0.000                 . 
BIC                            219.946           980.952          -761.006 
BIC used by Stata              372.203          1133.209          -761.006 
 
 
PRM            BIC=   980.952  AIC=    27.388  Pr fer  Over  Evidence 
------------------------------------------------------------------------- 
  vs NBRM      BIC=   219.946  dif=   761.006  NBRM    PRM   Very strong 
               AIC=     8.786  dif=    18.603  NBRM    PRM 
               LRX2=  764.719  prob=    0.000  NBRM    PRM   p=0.000     
------------------------------------------------------------------------- 

















Appendix 2: Search strategy for identification of eligible reviews (Chapter 5) 
 
 
Health Systems Evidence: 
Priority health system 
topics 
Governance arrangement OR Financial arrangement OR 
Delivery arrangement OR Implementation strategy 
Open search immunization (search title and abstract fields) 
OR 
immunisation (search title and abstract fields) 
OR 
vaccination (search title and abstract fields) 
Type of documents Systematic review OR policy brief OR systematic review 
protocol 
Limits  None 
Search output 27 records 
Cochrane Database of Systematic Reviews: 
Search all text ("Immunization"[Mesh] OR "Vaccination"[Mesh] OR 
"Immunization Programs"[Mesh]) 
Limits None 
Search output 338 records 
Database of Abstracts of Reviews of Effectiveness: 
Search all text (“Immunization”[Mesh] OR “Vaccination”[Mesh] OR 
“Immunization Programs”[Mesh]) 
Search output 160 records 
Limits None 
PubMed: 
Search terms ("Immunization"[Mesh] OR "Vaccination"[Mesh] OR 
"Immunization Programs"[Mesh]) 
Publication date 01 January 2000 to 31 March 2012 
Article type Systematic reviews 





















2. Immunization Schedule/ 
3. Immunization, Secondary/ 
4. Immunotherapy, Active/ 
5. Mass Immunization/ 
6. Immunization Programs/ 
7. Vaccination/ 
8. (vaccinat$ or revaccinat$ or immunization or immunisation or immunotherapy).tw. 
9. or/1-8 
10. Tetanus Toxoid/ 
11. Diphtheria Toxoid/ 
12. Diphtheria-Tetanus-Acellular Pertussis Vaccines/ 
13. Diphtheria-Tetanus-Pertussis Vaccine/ 
14. Diphtheria-Tetanus Vaccine/ 
15. Pertussis Vaccine/ 
16. Measles-Mumps-Rubella Vaccine/ 
17. Measles Vaccine/ 
18. Mumps Vaccine/ 
19. Rubella Vaccine/ 
20. Poliovirus Vaccines/ 
21. Poliovirus Vaccine, Inactivated/ 
22. Poliovirus Vaccine, Oral/ 
23. Tuberculosis Vaccines/ 
24. BCG Vaccine/ 
25. Viral Hepatitis Vaccines/ 
26. Hepatitis B Vaccines/ 
27. Haemophilus Vaccines/ 
28. ((tetanus or diphtheria) adj toxoid).tw. 
29. ((tetanus or diphtheria? or pertussis or whooping cough or measles or mumps or 
rubella? or rubeola or mmr or polio$ or tuberculosis or tuberculoses or bcg or 







36. Whooping Cough/ 
37. Poliomyelitis/ 
38. Poliomyelitis, Bulbar/ 
39. Tuberculosis/ 














41. Mycobacterium Tuberculosis/ 
42. Hepatitis B/ 
43. Hepatitis B, Chronic/ 
44. Haemophilus Influenzae/ 
45. Haemophilus Influenzae Type B/ 
46. (tetanus or diphtheria? or measles or rubella? or rubeola or mumps or epidemic 
parotit$ or pertussis or whooping cough or polio$ or infantile paralysis or tuberculosis 
or tuberculoses or hepatitis b or haemophilus influenza?).tw. 
47. or/31-46 
48. exp Child/ 
49. exp Infant/ 
50. exp Child Care/ 
51. (child$ or infant? or newborn? or neonat$ or baby or babies or kid? or 
toddler?).tw. 
52. or/48-51 
53. 9 and (Tetanus/ or tetanus.tw.) 
54. Tetanus Toxoid/ or (tetanus toxoid or tetanus vaccine? or tetanus prophylaxis).tw. 
55. 53 or 54 
56. Mothers/ 
57. Women/ 
58. Pregnant Women/ 
59. Female/ 
60. (woman or women or mother? or female?).tw. 
61. or/56-60 
62. 55 and 61 
63. Developing Countries.sh,kf. 
64. (Africa or Asia or Caribbean or West Indies or South America or Latin America or 
Central America).hw,kf,ti,ab,cp. 
65. (Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina 
or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or 
Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or 
Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or 
Botswana or Brazil or Brasil or Bulgaria or Burkina Faso or Burkina Fasso or Upper 
Volta or Burundi or Urundi or Cambodia or Khmer Republic or Kampuchea or 
Cameroon or Cameroons or Cameron or Camerons or Cape Verde or Central African 
Republic or Chad or Chile or China or Colombia or Comoros or Comoro Islands or 
Comores or Mayotte or Congo or Zaire or Costa Rica or Cote d'Ivoire or Ivory Coast 
or Croatia or Cuba or Cyprus or Czechoslovakia or Czech Republic or Slovakia or 
Slovak Republic or Djibouti or French Somaliland or Dominica or Dominican Republic 
or East Timor or East Timur or Timor Leste or Ecuador or Egypt or United Arab 
Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or 
Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic or 
Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or 
Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia 
or Iran or Iraq or Isle of Man or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya 














Kirghiz or Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho or 
Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy 
Republic or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or 
Nyasaland or Mali or Malta or Marshall Islands or Mauritania or Mauritius or Agalega 
Islands or Mexico or Micronesia or Middle East or Moldova or Moldovia or Moldovian 
or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or 
Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New Caledonia or 
Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat or 
Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or 
Philipines or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or 
Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or 
Saint Kitts or St Kitts or Nevis or Saint Lucia or St Lucia or Saint Vincent or St 
Vincent or Grenadines or Samoa or Samoan Islands or Navigator Island or Navigator 
Islands or Sao Tome or Saudi Arabia or Senegal or Serbia or Montenegro or 
Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or Solomon Islands or 
Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or 
Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or Togolese 
Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or 
Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or Union of 
Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or 
Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia 
or Zimbabwe or Rhodesia).hw,kf,ti,ab,cp. 
66. ((developing or less* developed or under developed or underdeveloped or middle 
income or low* income or underserved or under served or deprived or poor*) adj 
(countr* or nation? or population? or world)).ti,ab. 
67. ((developing or less* developed or under developed or underdeveloped or middle 
income or low* income) adj (economy or economies)).ti,ab. 
68. (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab. 
69. (low adj3 middle adj3 countr*).ti,ab. 
70. (lmic or lmics or third world or lami countr*).ti,ab. 
71. transitional countr*.ti,ab. 
72. or/63-71 
73. randomized controlled trial.pt. 
74. controlled clinical trial.pt. 
75. multicenter study.pt. 
76. (randomis* or randomiz* or randomly allocat* or random allocat*).ti,ab. 
77. groups.ab. 
78. (trial or multicenter or multi center or multicentre or multi centre).ti. 
79. (intervention* or controlled or control group or compare or compared or (before 
adj5 after) or (pre adj5 post) or pretest or pre test or posttest or post test or 
quasiexperiment* or quasi experiment* or evaluat* or effect or impact or time series 
or time point? or repeated measur*).ti,ab. 
80. or/73-79 
81. exp Animals/ 
82. Humans/ 



















89. cochrane database of systematic reviews.jn. 
90. comment on.cm. 
91. (systematic review or literature review).ti. 
92. or/83-91 
93. 80 not 92 
94. 9 and 47 and 52 and 72 and 93 
95. 30 and 52 and 72 and 93 
96. 62 and 72 and 93 





2. Active Immunization/ 
3. Mass Immunization/ 
4. Vaccination/ 
5. Revaccination/ 
6. (vaccinat$ or revaccinat$ or immunization or immunisation or immunotherapy).tw. 
7. or/1-6 
8. Tetanus Prophylaxis/ 
9. BCG Vaccination/ 
10. Measles Vaccination/ 
11. or/8-10 
12. Tetanus Toxoid/ 
13. Diphtheria Toxoid/ 
14. Diphtheria Toxoid crm197/ 
15. Diphtheria Tetanus Toxoid/ 
16. BCG Vaccine/ 
17. Diphtheria Pertussis Poliomyelitis Tetanus Haemophilus Influenzae Type B 
Hepatitis B Vaccine/ 
18. Diphtheria Pertussis Poliomyelitis Tetanus Vaccine/ 
19. Diphtheria Pertussis Tetanus Haemophilus Influenzae Type B Hepatitis B 
Vaccine/ 
20. Diphtheria Pertussis Tetanus Haemophilus Influenzae Type B Vaccine/ 
21. Diphtheria Pertussis Tetanus Vaccine/ 
22. Diphtheria Poliomyelitis Tetanus Vaccine/ 
23. Diphtheria Tetanus Vaccine/ 
24. Diphtheria Vaccine/ 
25. Haemophilus Influenzae Type B Hepatitis B Vaccine/ 
26. Haemophilus Influenzae Type B Vaccine/ 














28. Haemophilus Vaccine/ 
29. Pertussis Vaccine/ 
30. Triple Vaccine/ 
31. Hepatitis a Hepatitis B Vaccine/ 
32. Hepatitis B Vaccine/ 
33. Hepatitis Vaccine/ 
34. Recombinant Hepatitis B Vaccine/ 
35. Measles Mumps Rubella Vaccine/ 
36. Measles Mumps Vaccine/ 
37. Measles Rubella Vaccine/ 
38. Measles Vaccine/ 
39. Mumps Vaccine/ 
40. Rubella Vaccine/ 
41. Chickenpox Measles Mumps Rubella Vaccine/ 
42. Poliomyelitis Vaccine/ 
43. Oral Poliomyelitis Vaccine/ 
44. ((tetanus or diphtheria) adj toxoid).tw. 
45. ((tetanus or diphtheria? or pertussis or whooping cough or measles or mumps or 
rubella? or rubeola or mmr or polio$ or tuberculosis or tuberculoses or bcg or 










55. Lung Tuberculosis/ 
56. Mycobacterium Tuberculosis/ 
57. Hepatitis B/ 
58. Chronic Hepatitis/ 
59. Haemophilus Influenzae/ 
60. Haemophilus Influenzae Type B/ 
61. (tetanus or diphtheria? or measles or rubella? or rubeola or mumps or epidemic 
parotit$ or pertussis or whooping cough or polio$ or infantile paralysis or tuberculosis 
or tuberculoses or hepatitis b or haemophilus influenza?).tw. 
62. or/47-61 
63. exp Child/ 
64. exp Newborn/ 
65. Child Care/ 
66. (child$ or infant? or newborn? or neonat$ or baby or babies or kid? or 
toddler?).tw. 
67. or/63-66 














69. Tetanus Toxoid/ or Tetanus Prophylaxis/ or (tetanus toxoid or tetanus vaccin$ or 
tetanus prophylaxis).tw. 
70. or/68-69 
71. exp Mother/ 
72. Female/ 
73. (woman or women or mother? or female?).tw. 
74. or/71-73 
75. 70 and 74 
76. Developing Country.sh. 
77. (Africa or Asia or Caribbean or West Indies or South America or Latin America or 
Central America).hw,ti,ab,cp. 
78. (Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina 
or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or 
Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or 
Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or 
Botswana or Brazil or Brasil or Bulgaria or Burkina Faso or Burkina Fasso or Upper 
Volta or Burundi or Urundi or Cambodia or Khmer Republic or Kampuchea or 
Cameroon or Cameroons or Cameron or Camerons or Cape Verde or Central African 
Republic or Chad or Chile or China or Colombia or Comoros or Comoro Islands or 
Comores or Mayotte or Congo or Zaire or Costa Rica or Cote d'Ivoire or Ivory Coast 
or Croatia or Cuba or Cyprus or Czechoslovakia or Czech Republic or Slovakia or 
Slovak Republic or Djibouti or French Somaliland or Dominica or Dominican Republic 
or East Timor or East Timur or Timor Leste or Ecuador or Egypt or United Arab 
Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or 
Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic or 
Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or 
Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia 
or Iran or Iraq or Isle of Man or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya 
or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz Republic or 
Kirghiz or Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho or 
Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy 
Republic or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or 
Nyasaland or Mali or Malta or Marshall Islands or Mauritania or Mauritius or Agalega 
Islands or Mexico or Micronesia or Middle East or Moldova or Moldovia or Moldovian 
or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or 
Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New Caledonia or 
Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat or 
Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or 
Philipines or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or 
Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or 
Saint Kitts or St Kitts or Nevis or Saint Lucia or St Lucia or Saint Vincent or St 
Vincent or Grenadines or Samoa or Samoan Islands or Navigator Island or Navigator 
Islands or Sao Tome or Saudi Arabia or Senegal or Serbia or Montenegro or 
Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or Solomon Islands or 
Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or 














Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or 
Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or Union of 
Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or 
Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia 
or Zimbabwe or Rhodesia).hw,ti,ab,cp. 
79. ((developing or less* developed or under developed or underdeveloped or middle 
income or low* income or underserved or under served or deprived or poor*) adj 
(countr* or nation? or population? or world)).ti,ab. 
80. ((developing or less* developed or under developed or underdeveloped or middle 
income or low* income) adj (economy or economies)).ti,ab. 
81. (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab. 
82. (low adj3 middle adj3 countr*).ti,ab. 
83. (lmic or lmics or third world or lami countr*).ti,ab. 
84. transitional countr*.ti,ab. 
85. or/76-84 
86. Randomized Controlled Trial/ 
87. Controlled Clinical Trial/ 
88. Quasi Experimental Study/ 
89. Pretest Posttest Control Group Design/ 
90. Time Series Analysis/ 
91. Experimental Design/ 
92. Multicenter Study/ 
93. (randomis* or randomiz* or randomly or random allocat*).ti,ab. 
94. groups.ab. 
95. (trial or multicentre or multicenter or multi centre or multi center).ti. 
96. (intervention* or controlled or control group or compare or compared or (before 
adj5 after) or (pre adj5 post) or pretest or pre test or posttest or post test or 
quasiexperiment* or quasi experiment* or evaluat* or effect or impact or time series 
or time point? or repeated measur*).ti,ab. 
97. or/86-96 
98. (systematic review or literature review).ti. 
99. "cochrane database of systematic reviews".jn. 
100. Nonhuman/ 
101. or/98-100 
102. 97 not 101 
103. 7 and 62 and 67 and 85 and 102 
104. 11 and 67 and 85 and 102 
105. 46 and 67 and 85 and 102 




#1 MeSH descriptor Immunization, this term only 
#2 MeSH descriptor Immunization Schedule, this term only 














#4 MeSH descriptor Immunotherapy, Active, this term only 
#5 MeSH descriptor Mass Immunization, this term only 
#6 MeSH descriptor Immunization Programs, this term only 
#7 MeSH descriptor Vaccination, this term only 
#8 (vaccinat* or revaccinat* or immunization or immunisation or 
immunotherapy):ti,ab 
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) 
#10 MeSH descriptor Tetanus Toxoid, this term only 
#11 MeSH descriptor Diphtheria Toxoid, this term only 
#12 MeSH descriptor Diphtheria-Tetanus-acellular Pertussis Vaccines, this term 
only 
#13 MeSH descriptor Diphtheria-Tetanus-Pertussis Vaccine, this term only 
#14 MeSH descriptor Diphtheria-Tetanus Vaccine, this term only 
#15 MeSH descriptor Pertussis Vaccine, this term only 
#16 MeSH descriptor Measles-Mumps-Rubella Vaccine, this term only 
#17 MeSH descriptor Measles Vaccine, this term only 
#18 MeSH descriptor Mumps Vaccine, this term only 
#19 MeSH descriptor Rubella Vaccine, this term only 
#20 MeSH descriptor Poliovirus Vaccines, this term only 
#21 MeSH descriptor Poliovirus Vaccine, Inactivated, this term only 
#22 MeSH descriptor Poliovirus Vaccine, Oral, this term only 
#23 MeSH descriptor Tuberculosis Vaccines, this term only 
#24 MeSH descriptor BCG Vaccine, this term only 
#25 MeSH descriptor Viral Hepatitis Vaccines, this term only 
#26 MeSH descriptor Hepatitis B Vaccines, this term only 
#27 MeSH descriptor Haemophilus Vaccines, this term only 
#28 (tetanus NEXT toxoid or diphtheria NEXT toxoid):ti,ab 
#29 (tetanus NEXT vaccine* or diphtheria* NEXT vaccine* or pertussis NEXT 
vaccine* or whooping NEXT cough NEXT vaccine* or measles NEXT vaccine* 
or mumps NEXT vaccine* or rubella* NEXT vaccine* or rubeola NEXT 














NEXT vaccine* or tuberculoses NEXT vaccine* or bcg NEXT vaccine* or 
calmette* NEXT vaccine* or hepatitis NEXT b NEXT vaccine* or haemophilus 
NEXT vaccine* or triple NEXT vaccine*):ti,ab  
#30 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR 
#19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR 
#28 OR #29) 
#31 MeSH descriptor Tetanus, this term only 
#32 MeSH descriptor Diphtheria, this term only 
#33 MeSH descriptor Measles, this term only 
#34 MeSH descriptor Mumps, this term only 
#35 MeSH descriptor Rubella, this term only 
#36 MeSH descriptor Whooping Cough, this term only 
#37 MeSH descriptor Poliomyelitis, this term only 
#38 MeSH descriptor Poliomyelitis, Bulbar, this term only 
#39 MeSH descriptor Tuberculosis, this term only 
#40 MeSH descriptor Tuberculosis, Pulmonary, this term only 
#41 MeSH descriptor Mycobacterium tuberculosis, this term only 
#42 MeSH descriptor Hepatitis B, this term only 
#43 MeSH descriptor Hepatitis B, Chronic, this term only 
#44 MeSH descriptor Haemophilus influenzae, this term only 
#45 MeSH descriptor Haemophilus influenzae type b, this term only 
#46 (tetanus or diphtheria* or measles or rubella* or rubeola or mumps or epidemic 
NEXT parotit* or pertussis or whooping NEXT cough or polio* or infantile 
NEXT paralysis or tuberculosis or tuberculoses or hepatitis NEXT b or 
haemophilus NEXT influenza*):ti,ab 
#47 (#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR 
#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46) 
#48 MeSH descriptor Child explode all trees 
#49 MeSH descriptor Infant explode all trees 














#51 (child* or infant* or newborn* or neonat* or baby or babies or kid or kids or 
toddler*):ti,ab 
#52 (#48 OR #49 OR #50 OR #51) 
#53 MeSH descriptor Tetanus, this term only 
#54 tetanus:ti,ab 
#55 MeSH descriptor Tetanus Toxoid, this term only 
#56 (tetanus NEXT toxoid or tetanus NEXT vaccine* or tetanus NEXT 
prophylaxis):ti,ab 
#57 (#9 AND ( #53 OR #54 )) 
#58 (#55 OR #56) 
#59 (#57 OR #58) 
#60 MeSH descriptor Mothers, this term only 
#61 MeSH descriptor Women, this term only 
#62 MeSH descriptor Pregnant Women, this term only 
#63 (woman or women or mother or mothers or female*):ti,ab 
#64 (#60 OR #61 OR #62 OR #63) 
#65 (#59 AND #64) 
#66 (Africa or Asia or Caribbean or "West Indies" or "South America" or "Latin 
America" or "Central America"):ti,ab,kw 
#67 (Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or 
Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or 
Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or 
Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or 
Herzegovina or Hercegovina or Botswana or Brazil or Brasil or Bulgaria or 
"Burkina Faso" or "Burkina Fasso" or "Upper Volta" or Burundi or Urundi or 
Cambodia or "Khmer Republic" or Kampuchea or Cameroon or Cameroons or 
Cameron or Camerons or "Cape Verde" or "Central African Republic" or Chad 
or Chile or China or Colombia or Comoros or "Comoro Islands" or Comores or 
Mayotte or Congo or Zaire or "Costa Rica" or "Cote d'Ivoire" or "Ivory Coast" or 
Croatia or Cuba or Cyprus or Czechoslovakia or "Czech Republic" or Slovakia 














#68 (Djibouti or "French Somaliland" or Dominica or "Dominican Republic" or "East 
Timor" or "East Timur" or "Timor Leste" or Ecuador or Egypt or "United Arab 
Republic" or "El Salvador" or Eritrea or Estonia or Ethiopia or Fiji or Gabon or 
"Gabonese Republic" or Gambia or Gaza or Georgia or Georgian or Ghana or 
"Gold Coast" or Greece or Grenada or Guatemala or Guinea or Guam or 
Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or 
Indonesia or Iran or Iraq or "Isle of Man" or Jamaica or Jordan or Kazakhstan 
or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia 
or "Kyrgyz Republic" or Kirghiz or Kirgizstan or "Lao PDR" or Laos or Latvia or 
Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania):ti,ab,kw 
#69 (Macedonia or Madagascar or "Malagasy Republic" or Malaysia or Malaya or 
Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or 
"Marshall Islands" or Mauritania or Mauritius or "Agalega Islands" or Mexico or 
Micronesia or "Middle East" or Moldova or Moldovia or Moldovian or Mongolia 
or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or 
Burma or Namibia or Nepal or "Netherlands Antilles" or "New Caledonia" or 
Nicaragua or Niger or Nigeria or "Northern Mariana Islands" or Oman or 
Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or 
Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or 
"Puerto Rico"):ti,ab,kw 
#70 (Romania or Rumania or Roumania or Russia or Russian or Rwanda or 
Ruanda or "Saint Kitts" or "St Kitts" or Nevis or "Saint Lucia" or "St Lucia" or 
"Saint Vincent" or "St Vincent" or Grenadines or Samoa or "Samoan Islands" 
or "Navigator Island" or "Navigator Islands" or "Sao Tome" or "Saudi Arabia" or 
Senegal or Serbia or Montenegro or Seychelles or "Sierra Leone" or Slovenia 
or "Sri Lanka" or Ceylon or "Solomon Islands" or Somalia or Sudan or 
Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadzhikistan or 
Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or "Togolese Republic" 
or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or 
Turkmen or Uganda or Ukraine or Uruguay or USSR or "Soviet Union" or 














"New Hebrides" or Venezuela or Vietnam or "Viet Nam" or "West Bank" or 
Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia):ti,ab,kw 
#71 (developing or less* NEXT developed or "under developed" or underdeveloped 
or "middle income" or low* NEXT income or underserved or "under served" or 
deprived or poor*) NEXT (countr* or nation* or population* or world):ti,ab,kw 
#72 (developing or less* NEXT developed or "under developed" or underdeveloped 
or "middle income" or low* NEXT income) NEXT (economy or 
economies):ti,ab,kw 
#73 low* NEXT (gdp or gnp or "gross domestic" or "gross national"):ti,ab,kw 
#74 (low NEAR/3 middle NEAR/3 countr*):ti,ab,kw 
#75 (lmic or lmics or "third world" or "lami country" or "lami countries"):ti,ab,kw 
#76 ("transitional country" or "transitional countries"):ti,ab,kw 
#77 (#66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR 
#75 OR #76) 
#78 (#9 AND #47 AND #52 AND #77) 
#79 (#30 AND #52 AND #77) 
#80 (#65 AND #77) 




#  Query  
S95  S91 or S93 Exclude MEDLINE records 
S94  S91 or S93  
S93  S58 and S76 and S90  
S92  S24 and S43 and S76 and S90  
S91  S6 and S39 and S43 and S76 and S90  
S90  
S77 or S78 or S79 or S80 or S81 or S82 or S83 or S84 or S85 or S86 or S87 or 















TI ( (intervention* or controlled or control W0 group* or compare or compared or 
before N5 after or pre N5 post or pretest or "pre test" or posttest or "post test" or 
quasiexperiment* or quasi W0 experiment* or evaluat* or effect or impact or 
"time series" or time W0 point* or repeated W0 measur*) ) OR AB ( 
(intervention* or controlled or control W0 group* or compare or compared or 
before N5 after or pre N5 post or pretest or "pre test" or posttest or "post test" or 
quasiexperiment* or quasi W0 experiment* or evaluat* or effect or impact or 
"time series" or time W0 point* or repeated W0 measur*) )  
S88  
TI ( randomis* or randomiz* or random* W0 allocat* ) OR AB ( randomis* or 
randomiz* or random* W0 allocat* )  
S87  (MH "Health Services Research")  
S86  (MH "Multicenter Studies")  
S85  (MH "Quasi-Experimental Studies+")  
S84  (MH "Pretest-Posttest Design+")  
S83  (MH "Experimental Studies")  
S82  (MH "Nonrandomized Trials")  
S81  (MH "Intervention Trials")  
S80  (MH "Clinical Trials")  
S79  (MH "Randomized Controlled Trials")  
S78  PT research  
S77  PT clinical trial  
S76  
S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or 
S70 or S71 or S72 or S73 or S74 or S75  
S75  TI transitional W0 countr* OR AB transitional W0 countr*  
S74  
TI ( lmic or lmics or third W0 world or lami W0 countr* ) OR AB ( lmic or lmics or 














S73  TI low N3 middle N3 countr* OR AB low N3 middle N3 countr*  
S72  
TI ( low* W0 (gdp or gnp or gross W0 domestic or gross W0 national) ) OR AB ( 
low* W0 (gdp or gnp or gross W0 domestic or gross W0 national) )  
S71  
TI ( (developing or less* W0 developed or under W0 developed or 
underdeveloped or middle W0 income or low* W0 income) W0 (economy or 
economies) ) OR AB ( (developing or less* W0 developed or under W0 
developed or underdeveloped or middle W0 income or low* W0 income) W0 
(economy or economies) )  
S70  
TI ( (developing or less* W0 developed or under W0 developed or 
underdeveloped or middle W0 income or low* W0 income or underserved or 
under W0 served or deprived or poor*) W0 (countr* or nation or nations or 
population* or world or area or areas) ) OR AB ( (developing or less* W0 
developed or under W0 developed or underdeveloped or middle W0 income or 
low* W0 income or underserved or under W0 served or deprived or poor*) W0 
(countr* or nation or nations or population* or world or area or areas) )  
S69  
MW ( Afghanistan or Bangladesh or Benin or "Burkina Faso" or Burundi or 
Cambodia or "Central African Republic" or Chad or Comoros or Congo or "Cote 
d'Ivoire" or Eritrea or Ethiopia or Gambia or Ghana or Guinea or Haiti or India or 
Kenya or Korea or Kyrgyz or Kyrgyzstan or Lao or Laos or Liberia or 
Madagascar or Malawi or Mali or Mauritania or Melanesia or Mongolia or 
Mozambique or Burma or Myanmar or Nepal or Niger or Nigeria or Pakistan or 
Rwanda or "Salomon Islands" or "Sao Tome" or Senegal or "Sierra Leone" or 
Somalia or Sudan or Tajikistan or Tanzania or Timor or Togo or Uganda or 
Uzbekistan or Vietnam or "Viet Nam" or Yemen or Zambia or Zimbabwe ) or TI ( 
Afghanistan or Bangladesh or Benin or "Burkina Faso" or Burundi or Cambodia 
or "Central African Republic" or Chad or Comoros or Congo or "Cote d'Ivoire" or 
Eritrea or Ethiopia or Gambia or Ghana or Guinea or Haiti or India or Kenya or 
Korea or Kyrgyz or Kyrgyzstan or Lao or Laos or Liberia or Madagascar or 














Burma or Myanmar or Nepal or Niger or Nigeria or Pakistan or Rwanda or 
"Salomon Islands" or "Sao Tome" or Senegal or "Sierra Leone" or Somalia or 
Sudan or Tajikistan or Tanzania or Timor or Togo or Uganda or Uzbekistan or 
Vietnam or "Viet Nam" or Yemen or Zambia or Zimbabwe ) or AB ( Afghanistan 
or Bangladesh or Benin or "Burkina Faso" or Burundi or Cambodia or "Central 
African Republic" or Chad or Comoros or Congo or "Cote d'Ivoire" or Eritrea or 
Ethiopia or Gambia or Ghana or Guinea or Haiti or India or Kenya or Korea or 
Kyrgyz or Kyrgyzstan or Lao or Laos or Liberia or Madagascar or Malawi or Mali 
or Mauritania or Melanesia or Mongolia or Mozambique or Burma or Myanmar 
or Nepal or Niger or Nigeria or Pakistan or Rwanda or "Salomon Islands" or 
"Sao Tome" or Senegal or "Sierra Leone" or Somalia or Sudan or Tajikistan or 
Tanzania or Timor or Togo or Uganda or Uzbekistan or Vietnam or "Viet Nam" 
or Yemen or Zambia or Zimbabwe )  
S68  
MW ( Albania or Algeria or Angola or Armenia or Azerbaijan or Belarus or 
Bhutan or Bolivia or Bosnia or Herzegovina or "Cape Verde" or Cameroon or 
China or Colombia or Congo or Cuba or Djibouti or "Dominican Republic" or 
Ecuador or Egypt or "El Salvador" or Fiji or Gaza or Georgia or Guam or 
Guatemala or Guyana or Honduras or "Indian Ocean Islands" or Indonesia or 
Iran or Iraq or Jamaica or Jordan or Kiribati or Lesotho or Macedonia or 
Maldives or "Marshall Islands" or Micronesia or "Middle East" or Moldova or 
Morocco or Namibia or Nicaragua or Palestin* or Paraguay or Peru or 
Philippines or Samoa or "Sri Lanka" or Suriname or Swaziland or Syria or 
"Syrian Arab Republic" or Thailand or Tonga or Tunisia or Turkmenistan or 
Ukraine or Vanuatu or "West Bank" ) or TI ( Albania or Algeria or Angola or 
Armenia or Azerbaijan or Belarus or Bhutan or Bolivia or Bosnia or Herzegovina 
or "Cape Verde" or Cameroon or China or Colombia or Congo or Cuba or 
Djibouti or "Dominican Republic" or Ecuador or Egypt or "El Salvador" or Fiji or 
Gaza or Georgia or Guam or Guatemala or Guyana or Honduras or "Indian 
Ocean Islands" or Indonesia or Iran or Iraq or Jamaica or Jordan or Kiribati or 














"Middle East" or Moldova or Morocco or Namibia or Nicaragua or Palestin* or 
Paraguay or Peru or Philippines or Samoa or "Sri Lanka" or Suriname or 
Swaziland or Syria or "Syrian Arab Republic" or Thailand or Tonga or Tunisia or 
Turkmenistan or Ukraine or Vanuatu or "West Bank" ) or AB ( Albania or Algeria 
or Angola or Armenia or Azerbaijan or Belarus or Bhutan or Bolivia or Bosnia or 
Herzegovina or "Cape Verde" or Cameroon or China or Colombia or Congo or 
Cuba or Djibouti or "Dominican Republic" or Ecuador or Egypt or "El Salvador" 
or Fiji or Gaza or Georgia or Guam or Guatemala or Guyana or Honduras or 
"Indian Ocean Islands" or Indonesia or Iran or Iraq or Jamaica or Jordan or 
Kiribati or Lesotho or Macedonia or Maldives or "Marshall Islands" or Micronesia 
or "Middle East" or Moldova or Morocco or Namibia or Nicaragua or Palestin* or 
Paraguay or Peru or Philippines or Samoa or "Sri Lanka" or Suriname or 
Swaziland or Syria or "Syrian Arab Republic" or Thailand or Tonga or Tunisia or 
Turkmenistan or Ukraine or Vanuatu or "West Bank" )  
S67  
MW ( "American Samoa" or Argentina or Belize or Botswana or Brazil or Brasil 
or Bulgaria or Chile or Comoros or "Costa Rica" or Croatia or Dominica or 
Guinea or Gabon or Grenada or Grenadines or Hungary or Kazakhstan or 
Latvia or Lebanon or Libia or libyan or Libya or Lithuania or Malaysia or 
Mauritius or Mayotte or Mexico or Micronesia or Montenegro or Nevis or 
"Northern Mariana Islands" or Oman or Palau or Panama or Poland or Romania 
or Russia or "Russian Federation" or Samoa or "Saint Lucia" or "St Lucia" or 
"Saint Kitts" or "St Kitts" or "Saint Vincent" or "St Vincent" or Serbia or 
Seychelles or Slovakia or "Slovak Republic" or "South Africa" or Turkey or 
Uruguay or Venezuela or Yugoslavia ) or TI ( "American Samoa" or Argentina or 
Belize or Botswana or Brazil or Bulgaria or Chile or Comoros or "Costa Rica" or 
Croatia or Dominica or Guinea or Gabon or Grenada or Grenadines or Hungary 
or Kazakhstan or Latvia or Lebanon or Libia or libyan or Libya or Lithuania or 
Malaysia or Mauritius or Mayotte or Mexico or Micronesia or Montenegro or 
Nevis or "Northern Mariana Islands" or Oman or Palau or Panama or Poland or 














Lucia" or "Saint Kitts" or "St Kitts" or "Saint Vincent" or "St Vincent" or Serbia or 
Seychelles or Slovakia or "Slovak Republic" or "South Africa" or Turkey or 
Uruguay or Venezuela or Yugoslavia ) or AB ( "American Samoa" or Argentina 
or Belize or Botswana or Brazil or Bulgaria or Chile or Comoros or "Costa Rica" 
or Croatia or Dominica or Guinea or Gabon or Grenada or Grenadines or 
Hungary or Kazakhstan or Latvia or Lebanon or Libia or libyan or Libya or 
Lithuania or Malaysia or Mauritius or Mayotte or Mexico or Micronesia or 
Montenegro or Nevis or "Northern Mariana Islands" or Oman or Palau or 
Panama or Poland or Romania or Russia or "Russian Federation" or Samoa or 
"Saint Lucia" or "St Lucia" or "Saint Kitts" or "St Kitts" or "Saint Vincent" or "St 
Vincent" or Serbia or Seychelles or Slovakia or "Slovak Republic" or "South 
Africa" or Turkey or Uruguay or Venezuela or Yugoslavia )  
S66  
TI ( Africa or Asia or "South America" or "Latin America" or "Central America" ) 
or AB ( Africa or Asia or "South America" or "Latin America" or "Central 
America" )  
S65  (MH "Asia+")  
S64  (MH "West Indies+")  
S63  (MH "South America+")  
S62  (MH "Latin America")  
S61  (MH "Central America+")  
S60  (MH "Africa+")  
S59  (MH "Developing Countries")  
S58  S51 and S57  
S57  S52 or S53 or S54 or S55 or S56  
S56  
TI ( woman or women or mother* or female* ) or AB ( woman or women or 
mother* or female* )  














S54  (MH "Expectant Mothers")  
S53  (MH "Women")  
S52  (MH "Mothers")  
S51  S47 or S50  
S50  S48 or S49  
S49  
TI ( "tetanus toxoid" or "tetanus vaccine" or "tetanus vaccines" or "tetanus 
prophylaxis" ) or AB ( "tetanus toxoid" or "tetanus vaccine" or "tetanus vaccines" 
or "tetanus prophylaxis" )  
S48  (MH "Tetanus Toxoid")  
S47  S6 and S46  
S46  S44 or S45  
S45  TI tetanus or AB tetanus  
S44  (MH "Tetanus")  
S43  S40 or S41 or S42  
S42  
TI ( child* or infant* or newborn* or neonat* or baby or babies or kid or kids or 
toddler* ) or AB ( child* or infant* or newborn* or neonat* or baby or babies or 
kid or kids or toddler* )  
S41  (MH "Child Care+")  
S40  (MH "Child+")  
S39  
S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or 
S36 or S37 or S38  
S38  
TI ( tetanus or diphtheria* or measles or rubella* or rubeola or mumps or 
epidemic W1 parotid* or pertussis or "whooping cough" or polio* or "infantile 
paralysis" or tuberculosis or tuberculoses or "hepatitis b" or "haemophilus 
influenza" or "haemophilus influenzae" or "haemophilus flue" ) or AB ( tetanus or 














or pertussis or "whooping cough" or polio* or "infantile paralysis" or tuberculosis 
or tuberculoses or "hepatitis b" or "haemophilus influenza" or "haemophilus 
influenzae" or "haemophilus flue" )  
S37  (MH "Haemophilus Influenzae")  
S36  (MH "Hepatitis B, Chronic")  
S35  (MH "Hepatitis B")  
S34  (MH "Mycobacterium Tuberculosis")  
S33  (MH "Tuberculosis, Pulmonary")  
S32  (MH "Tuberculosis")  
S31  (MH "Poliomyelitis")  
S30  (MH "Whooping Cough")  
S29  (MH "Rubella")  
S28  (MH "Mumps")  
S27  (MH "Measles")  
S26  (MH "Diphtheria")  
S25  (MH "Tetanus")  
S24  
S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or 
S18 or S19 or S20 or S21 or S22 or S23  
S23  
TI ( tetanus W1 vaccine* or diphtheria* W1 vaccine* or pertussis W1 vaccine* or 
"whooping cough" W1 vaccine* or measles W1 vaccine* or mumps W1 vaccine* 
or rubella* W1 vaccine* or rubeola W1 vaccine* or mmr W1 vaccine* or polio* 
W1 vaccine* or tuberculosis W1 vaccine* or tuberculoses W1 vaccine* or bcg 
W1 vaccine* or calmette* W1 vaccine* or "hepatitis b" W1 vaccine* or 
haemophilus W1 vaccine* or hib W1 vaccine* or triple W1 vaccine* ) or AB ( 
tetanus W1 vaccine* or diphtheria* W1 vaccine* or pertussis W1 vaccine* or 














or rubella* W1 vaccine* or rubeola W1 vaccine* or mmr W1 vaccine* or polio* 
W1 vaccine* or tuberculosis W1 vaccine* or tuberculoses W1 vaccine* or bcg 
W1 vaccine* or calmette* W1 vaccine* or "hepatitis b" W1 vaccine* or 
haemophilus W1 vaccine* or hib W1 vaccine* or triple W1 vaccine* )  
S22  
TI ( "tetanus toxoid" or "diphtheria toxoid" ) or AB ( "tetanus toxoid" or 
"diphtheria toxoid" )  
S21  (MH "HIB Vaccine")  
S20  (MH "Hepatitis B Vaccines")  
S19  (MH "Viral Hepatitis Vaccines")  
S18  (MH "BCG Vaccine")  
S17  (MH "Poliovirus Vaccine")  
S16  (MH "Rubella Vaccine")  
S15  (MH "Mumps Vaccine")  
S14  (MH "Measles Vaccine")  
S13  (MH "Measles-Mumps-Rubella Vaccine")  
S12  (MH "Pertussis Vaccine")  
S11  (MH "Diphtheria-Tetanus Vaccine")  
S10  (MH "Diphtheria-Tetanus-Pertussis Vaccine")  
S9  (MH "Diphtheria-Tetanus-acellular Pertussis Vaccines")  
S8  (MH "Diphtheria Toxoid")  
S7  (MH "Tetanus Toxoid")  
S6  S1 or S2 or S3 or S4 or S5  
S5  
TI ( (vaccinat* or revaccinate* or immunization or immunisation or 
immunotherapy) ) or AB ( (vaccinat* or revaccinate* or immunization or 














S4  (MH "Immunization Programs")  
S3  (MH "Immunotherapy")  
S2  (MH "Immunization Schedule")  
S1  (MH "Immunization")  
 
 
Sociological Abstracts (ProQuest) 
ALL(vaccination or vaccine or vaccines or immunization) 
AND 
ALL(child* or infant* or newborn or neonat* or baby or babies or kid or kids or 
toddler* or mother* or woman or women or female)  
 
LILACS (VHL) 
(immunization or inmunizacion or imunizacao or vaccination or vacunacion or 
vacinacao or vaccine or vaccines or vacuna or vacunas or vacina or vacinas) AND 
(tetanus or tetanico or diphtheria or difterico or pertussis or "whooping cough" or 
tosferina or "tos ferina" or "tos convulsa" or "tosse convulsa" or coqueluche or 
measles or sarampion or sarampo or mumps or paperas or caxumba or rubella or 
rubeola or mmr or polio* or tubercul* or "mycobacterium bovis" or bcg or calmette* or 
hepatitis or hepatite or haemophilus) AND (child or children or infant or infants or 
newborn or neonat* or baby or babies or kid or kids or toddler* or nino or ninos or 
crianca or criancas or lactante* or lactente* or "recien nacido" or "recien nacidos" or 
"recem nascido" or "recem nascidos") AND (randomi* or randomly or azar or acaso 
or control* or intervention* or evaluat* or effect* or impact or impacts or intervencion* 
or intervencao* or evaluar or evaluacion or avaliacao or efecto or efectos or efeito or 
efeitos or impacto or impactos or "serie de tiempo" or "series de tiempo" or "serie de 
tempo" or "series de tempo" or "serie temporal" or "series temporal" or "serie 
temporales" or "series temporales" or "serie temporais" or "series temporais" or 
"puntos de tiempo" or "pontos de tiempo" or "puntos de tempo" or "puntos de tempo" 
or "puntos temporales" or "pontos temporales" or "punto temporais" or "ponto 














"medidas repetidas" or "medicion repetida" or "medicion repetidas" or "mediciones 
repetida" or "mediciones repetidas")  
 
 
 
